[10-Q] LifeMD, Inc. Quarterly Earnings Report
LifeMD, Inc. reported stronger Q3 2025 results, with total revenue rising to $60.2 million from $53.3 million a year earlier, driven by growth in telehealth and steady WorkSimpli software subscriptions. For the first nine months of 2025, revenue reached $187.0 million, up from $149.3 million in the prior-year period, while the operating loss narrowed sharply to $1.4 million from $14.4 million.
Net loss attributable to common stockholders improved to $4.6 million in the quarter and $7.9 million year-to-date, compared with $5.4 million and $18.8 million in the prior-year periods, despite ongoing preferred dividends of $2.3 million for the nine months. LifeMD generated $11.6 million of cash from operations year-to-date, repaid its remaining $14.0 million Avenue credit facility, and ended September 30, 2025 with $23.8 million in cash and positive stockholders’ equity of $3.4 million. Management states that existing cash should fund planned operations and capital needs for at least the next 12 months.
- Revenue growth and margin scale: Total revenue increased to $60.2 million for Q3 2025 and $186.98 million year-to-date, with gross profit of $163.49 million for the nine months, supporting improved operating leverage.
- Improving profitability and cash generation: Nine‑month operating loss narrowed to $1.45 million from $14.43 million, while net cash provided by operating activities reached $11.56 million.
- Balance sheet de-risking: LifeMD fully repaid the remaining $14.0 million principal on its Avenue credit facility and ended September 30, 2025 with $23.79 million in cash and positive stockholders’ equity of $3.37 million.
- None.
Insights
LifeMD shows double-digit revenue growth, improved losses, and deleverages its balance sheet.
LifeMD’s Q3 2025 revenue rose to
Cost discipline is evident in the sharply reduced operating loss of
At
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
For
the Quarterly Period Ended
or
For the Transition Period from _________ to _________
Commission
file number:
(Exact name of registrant as specified in its charter)
(State or other Jurisdiction of Incorporation or Organization) |
(I.R.S. Employer Identification No.) |
| (Address of Principal Executive Offices) | (Zip Code) |
(Registrant’s telephone number, including area code)
Securities registered pursuant to Section 12(b) of the Act:
| Title of each class | Trading symbol(s) | Name of exchange on which registered | ||
Indicate
by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange
Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)
has been subject to such filing requirements for the past 90 days.
Indicate
by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule
405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant
was required to submit such files).
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a small reporting company. See the definitions of “large accelerated filer,” “accelerated filer,” a “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
| Large
|
☐ | Accelerated filer | ☒ |
| Non-accelerated filer | ☐ | Smaller reporting company | |
| Emerging growth company |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act: ☐
Indicate
by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No
As
of November 14, 2025, there were
LIFEMD, INC.
FORM 10-Q
FOR THE QUARTERLY PERIOD ENDED SEPTEMBER 30, 2025
TABLE OF CONTENTS
| Page | ||
| PART I. FINANCIAL INFORMATION | 3 | |
| ITEM 1. | Financial Statements (unaudited) | 3 |
| Condensed Consolidated Balance Sheets | 3 | |
| Condensed Consolidated Statements of Operations | 4 | |
| Condensed Consolidated Statements of Stockholders’ Equity (Deficit) | 5 | |
| Condensed Consolidated Statements of Cash Flows | 7 | |
| Notes to Condensed Consolidated Financial Statements | 8 | |
| ITEM 2. | Management’s Discussion and Analysis of Financial Condition and Results of Operations | 30 |
| ITEM 3. | Quantitative and Qualitative Disclosures about Market Risk | 39 |
| ITEM 4. | Controls and Procedures | 39 |
| PART II. OTHER INFORMATION | 41 | |
| ITEM 1. | Legal Proceedings | 41 |
| ITEM 1A. | Risk Factors | 41 |
| ITEM 2. | Unregistered Sales of Equity Securities and Use of Proceeds | 41 |
| ITEM 3. | Defaults Upon Senior Securities | 41 |
| ITEM 4. | Mine Safety Disclosures | 41 |
| ITEM 5. | Other Information | 41 |
| ITEM 6. | Exhibits | 42 |
| SIGNATURES | 43 | |
2
PART I – FINANCIAL INFORMATION
Item 1. Financial Statements
LIFEMD, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(Unaudited)
| September 30, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash | $ | $ | ||||||
| Accounts receivable | ||||||||
| Product deposit | ||||||||
| Inventory | ||||||||
| Other current assets | ||||||||
| Total Current Assets | ||||||||
| Non-current Assets | ||||||||
| Equipment, net | ||||||||
| Right of use assets, net | ||||||||
| Capitalized software, net | ||||||||
| Intangible assets, net | ||||||||
| Total Non-current Assets | ||||||||
| Total Assets | $ | $ | ||||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY (DEFICIT) | ||||||||
| Current Liabilities | ||||||||
| Accounts payable | $ | $ | ||||||
| Accrued expenses | ||||||||
| Current operating lease liabilities | ||||||||
| Current portion of convertible long-term debt | - | |||||||
| Deferred revenue | ||||||||
| Total Current Liabilities | ||||||||
| Long-term Liabilities | ||||||||
| Convertible long-term debt, net | - | |||||||
| Noncurrent operating lease liabilities | ||||||||
| Contingent consideration | ||||||||
| Total Liabilities | ||||||||
| Commitments and contingencies (Note 11) | - | |||||||
| Stockholders’ Equity (Deficit) | ||||||||
| Series A Preferred Stock, $ | ||||||||
| Common Stock, $ | ||||||||
| Additional paid-in capital | ||||||||
| Accumulated deficit | ( | ) | ( | ) | ||||
| Treasury stock, | ( | ) | ( | ) | ||||
| Total LifeMD, Inc. Stockholders’ Equity (Deficit) | ( | ) | ||||||
| Non-controlling interest | ||||||||
| Total Stockholders’ Equity (Deficit) | ( | ) | ||||||
| Total Liabilities and Stockholders’ Equity (Deficit) | $ | $ | ||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
3
LIFEMD, INC.
CONDENSED Consolidated STATEMENTS OF OPERATIONS
(Unaudited)
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Revenues | ||||||||||||||||
| Telehealth revenue, net | $ | $ | $ | $ | ||||||||||||
| WorkSimpli revenue, net | ||||||||||||||||
| Total revenues, net | ||||||||||||||||
| Cost of revenues | ||||||||||||||||
| Cost of telehealth revenue | ||||||||||||||||
| Cost of WorkSimpli revenue | ||||||||||||||||
| Total cost of revenues | ||||||||||||||||
| Gross profit | ||||||||||||||||
| Expenses | ||||||||||||||||
| Selling and marketing expenses | ||||||||||||||||
| General and administrative expenses | ||||||||||||||||
| Customer service expenses | ||||||||||||||||
| Other operating expenses | ||||||||||||||||
| Development costs | ||||||||||||||||
| Total expenses | ||||||||||||||||
| Operating loss | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Interest expense, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss on debt extinguishment | ( | ) | - | ( | ) | - | ||||||||||
| Net loss before income taxes | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Income tax expense | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net income (loss) | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net income (loss) attributable to non-controlling interest | ( | ) | ||||||||||||||
| Net loss attributable to LifeMD, Inc. | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Preferred stock dividends | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Basic loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Weighted average number of common shares outstanding: | ||||||||||||||||
| Basic | ||||||||||||||||
| Diluted | ||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
4
LIFEMD, INC.
CONDENSED Consolidated STATEMENTS of CHANGES IN STOCKHOLDERS’ EQUITY (Deficit)
(Unaudited)
| Shares | Amount | Shares | Amount | Capital | Deficit | Stock | Total | Interest | Total | |||||||||||||||||||||||||||||||
| LifeMD, Inc. | ||||||||||||||||||||||||||||||||||||||||
| Series A Preferred Stock | Common Stock | Additional Paid-in | Accumulated | Treasury | Non- controlling | |||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Stock | Total | Interest | Total | |||||||||||||||||||||||||||||||
| Balance, January 1, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||||||
| Stock compensation expense | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Stock issued for noncontingent consideration payment | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Exercise of stock options | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Cashless exercise of warrants | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Cashless exercise of options | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Series A Preferred Stock Dividend | - | - | - | - | - | ( | ) | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Net (loss) income | - | - | - | - | - | ( | ) | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance, March 31, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||||||
| Stock compensation expense | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Exercise of stock options | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Cashless exercise of stock options | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Cashless exercise of warrants | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Series A Preferred Stock Dividend | - | - | - | - | - | ( | ) | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Net (loss) income | - | - | - | - | - | ( | ) | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance, June 30, 2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||
| Stock compensation expense | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Series A Preferred Stock Dividend | - | - | - | - | - | ( | ) | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Net loss | - | - | - | - | - | ( | ) | - | ( | ) | ( | ) | ( | ) | ||||||||||||||||||||||||||
| Balance, September 30,2024 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||||||||||||||||||||||||
5
| LifeMD, Inc. | ||||||||||||||||||||||||||||||||||||||||
| Series A Preferred Stock | Common Stock | Additional Paid-in | Accumulated | Treasury | Non- controlling | |||||||||||||||||||||||||||||||||||
| Shares | Amount | Shares | Amount | Capital | Deficit | Stock | Total | Interest | Total | |||||||||||||||||||||||||||||||
| Balance, January 1, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||
| Stock compensation expense | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Cashless exercise of stock options | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Series A Preferred Stock Dividend | - | - | - | - | - | ( | ) | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Net income | - | - | - | - | - | ( | ) | - | ( | ) | ||||||||||||||||||||||||||||||
| Balance, March 31, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||
| Stock compensation expense | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Cashless exercise of stock options | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Cashless exercise of warrants | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Stock issued for debt conversion | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Stock issued for asset acquisition | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Series A Preferred Stock Dividend | - | - | - | - | - | ( | ) | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Net (loss) income | - | - | - | - | - | ( | ) | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance, June 30, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | $ | ( | ) | ||||||||||||||||||||||||
| Stock compensation expense | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Cashless exercise of stock options | - | - | ( | ) | - | - | - | - | - | |||||||||||||||||||||||||||||||
| Exercise of stock options | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Exercise of warrants | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Sale of common stock under ATM, net | - | - | - | - | - | |||||||||||||||||||||||||||||||||||
| Series A Preferred Stock Dividend | - | - | - | - | - | ( | ) | - | ( | ) | - | ( | ) | |||||||||||||||||||||||||||
| Distribution to non-controlling interest | - | - | - | - | - | - | - | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Net (loss) income | - | - | - | - | - | ( | ) | - | ( | ) | ( | ) | ||||||||||||||||||||||||||||
| Balance, September 30, 2025 | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||||||
| Balance | $ | $ | $ | $ | ( | ) | $ | ( | ) | $ | $ | $ | ||||||||||||||||||||||||||||
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
6
LIFEMD, INC.
CONDENSED Consolidated STATEMENTS OF CASH FLOWS
(Unaudited)
| 2025 | 2024 | |||||||
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| CASH FLOWS FROM OPERATING ACTIVITIES | ||||||||
| Net loss | $ | ( | ) | $ | ( | ) | ||
| Adjustments to reconcile net loss to net cash provided by operating activities: | ||||||||
| Amortization of debt discount | ||||||||
| Amortization of capitalized software | ||||||||
| Amortization of intangibles | ||||||||
| Accretion of consideration payable | - | |||||||
| Loss on debt extinguishment | - | |||||||
| Depreciation of fixed assets | ||||||||
| Noncash operating lease expense | ||||||||
| Stock compensation expense | ||||||||
| Changes in Assets and Liabilities | ||||||||
| Accounts receivable | ( | ) | ||||||
| Product deposit | ( | ) | ||||||
| Inventory | ( | ) | ||||||
| Other current assets | ( | ) | ( | ) | ||||
| Operating lease liabilities | ( | ) | ( | ) | ||||
| Deferred revenue | ( | ) | ||||||
| Accounts payable | ||||||||
| Accrued expenses | ( | ) | ||||||
| Net cash provided by operating activities | ||||||||
| CASH FLOWS FROM INVESTING ACTIVITIES | ||||||||
| Cash paid for capitalized software costs(a) | ( | ) | ( | ) | ||||
| Purchase of equipment | ( | ) | ( | ) | ||||
| Purchase of intangible assets | - | ( | ) | |||||
| Net cash used in investing activities | ( | ) | ( | ) | ||||
| CASH FLOWS FROM FINANCING ACTIVITIES | ||||||||
| Repayment of debt instruments | ( | ) | - | |||||
| Sale of common stock under ATM, net | - | |||||||
| Preferred stock dividends | ( | ) | ( | ) | ||||
| Repayment of notes payable, net of prepayment penalty | - | ( | ) | |||||
| Cash proceeds from exercise of warrants | - | |||||||
| Cash proceeds from exercise of options | ||||||||
| Contingent consideration payments for ResumeBuild acquisition | - | ( | ) | |||||
| Distributions to non-controlling interest | ( | ) | ( | ) | ||||
| Net cash used in financing activities | ( | ) | ( | ) | ||||
| Net (decrease) increase in cash | ( | ) | ||||||
| Cash at beginning of period | ||||||||
| Cash at end of period | $ | $ | ||||||
| Cash paid for interest and taxes | ||||||||
| Cash paid during the period for interest | $ | $ | ||||||
| Cash paid during the period for taxes | $ | $ | ||||||
| Non-cash investing and financing activities: | ||||||||
| Cashless exercise of options | $ | $ | ||||||
| Cashless exercise of warrants | $ | $ | ||||||
| Stock issued for debt conversion | $ | $ | - | |||||
| Stock issued for asset acquisition | $ | $ | - | |||||
| Stock issued for noncontingent consideration payment | $ | - | $ | |||||
| Right of use assets | $ | - | $ | |||||
| Operating lease liabilities | $ | - | $ | |||||
| (a) |
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.
7
LIFEMD, INC.
NOTES TO UNAUDITED CONDENSED CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1 – NATURE OF THE ORGANIZATION AND BUSINESS
Corporate History
LifeMD,
Inc. was formed in the State of Delaware on May 24, 1994, under its prior name, Immudyne, Inc. The Company changed its name to Conversion
Labs, Inc. on June 22, 2018 and then subsequently, on February 22, 2021, it changed its name to LifeMD, Inc. Effective February 22, 2021,
the trading symbol for the Company’s common stock, par value $
On
April 1, 2016, the original operating agreement of Immudyne PR LLC (“Immudyne PR”), a joint venture to market the Company’s
skincare products, was amended and restated and the Company increased its ownership and voting interest in Immudyne PR to
In
June 2018, the Company closed the strategic acquisition of
Unless otherwise indicated, the terms “LifeMD,” “Company,” “we,” “us,” and “our” refer to LifeMD, Inc. (formerly known as Conversion Labs, Inc.), LifeMD Pharmacy Holdings LLC, an affiliated limited liability company, (“LifeMD Pharmacy”) and our majority-owned subsidiary, WorkSimpli. The affiliated network of medical Professional Corporations and medical Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C. (“LifeMD PC”) is the Company’s affiliated, variable interest entity in which we hold a controlling financial interest. Unless otherwise specified, all dollar amounts are expressed in United States dollars.
Nature of Business
The Company is a direct-to-patient telehealth company providing virtual and in-home healthcare. The Company is improving the delivery of the healthcare experience through telehealth with its proprietary technology platform, affiliated and dedicated provider network, broad and expanding treatment capabilities, and the unique ability to nurture patient relationships. Direct-to-patient telehealth technology companies, like the Company, connect consumers to affiliated, licensed, healthcare professionals for care across numerous indications, including virtual medical care, weight loss, sexual health, hormone replacement therapy, hair loss and other conditions.
The Company’s telehealth platform helps patients access their licensed providers for diagnoses, virtual care, and prescription medications, often delivered on a recurring basis. In addition to its telehealth prescription offerings, the Company sells over-the-counter (“OTC”) products. All products are available on a subscription or membership basis, where a patient can subscribe to receive regular shipments of prescribed medications or products. This creates convenience and often discounted pricing opportunities for patients and recurring revenue streams for the Company.
With its first brand, ShapiroMD, the Company has built a full line of proprietary OTC products for male and female hair loss including Food and Drug Administration (“FDA”) approved OTC minoxidil and an FDA-cleared medical device and a personalized telehealth platform offering that gives consumers access to virtual medical treatment from their providers and, when appropriate, a full line of oral and topical prescription medications for hair loss. The Company’s men’s brand, RexMD, currently offers access to virtual medical treatment for a variety of men’s health needs, including erectile dysfunction, premature ejaculation and hair loss.
In the first quarter of 2022, the Company launched our virtual primary care offering under the LifeMD brand, LifeMD Primary Care. This offering provides patients with access to affiliated high-quality providers for their urgent care and chronic care needs.
In April 2023, we launched our GLP-1 Weight Management Program providing primary care, metabolic coaching, lab work, and prescription services (as appropriate) to patients seeking to access a medically supported weight loss solution. In September 2024, we expanded our Weight Management Program with a personalized, non-GLP-1 treatment plan consisting of three oral medications – metformin, bupropion, and topiramate.
8
Liquidity Evaluation
As
of September 30, 2025, the Company has an accumulated deficit of approximately $
On
March 21, 2023, the Company entered into and closed on a loan and security agreement (the “Avenue Credit Agreement”), and
a supplement to the Credit Agreement (the “Avenue Supplement”), with Avenue Venture Opportunities Fund II, L.P. and Avenue
Venture Opportunities Fund, L.P. (collectively, “Avenue”). The Avenue Credit Agreement provided for a convertible senior
secured credit facility of up to an aggregate amount of $
The
Company entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc. and
Cantor Fitzgerald & Co. relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company
may, but is not obligated to, offer and sell, from time to time, shares of common stock, through or to the Agents, acting as agent or
principal. Sales of common stock, if any, will be made by any method permitted that is deemed an “at the market offering”
as defined in Rule 415 under the Securities Act. On June 7, 2024, the Company filed a shelf registration statement on Form S-3 under
the Securities Act, which was declared effective on July 18, 2024 (the “2024 Shelf”). Under the 2024 Shelf at the time of
effectiveness, the Company had the ability to raise up to $
The Company expects that its existing cash as of September 30, 2025 of $
NOTE 2 – BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and in accordance with the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and note disclosures required by accounting principles generally accepted in the United States (“U.S. GAAP”) for complete audited financial statements. The accompanying unaudited financial information should be read in conjunction with the audited consolidated financial statements, including the notes thereto, as of and for the year ended December 31, 2024, included in our 2024 Annual Report on Form 10-K filed with the SEC. The information furnished in this report reflects all adjustments (consisting of normal recurring adjustments), which are, in the opinion of management, necessary for the fair statement of our financial position, results of operations and cash flows for each period presented. The results of operations for the three and nine months ended September 30, 2025 are not necessarily indicative of the results for the year ending December 31, 2025 or for any future period.
9
Principles of Consolidation
The Company evaluates the need to consolidate affiliates based on standards set forth in Accounting Standards Codification (“ASC”) 810, Consolidation. The unaudited condensed consolidated financial statements include the accounts of the Company, LifeMD Pharmacy, its majority owned subsidiary, WorkSimpli, and LifeMD PC, the Company’s affiliated, variable interest entity in which we hold a controlling financial interest. All intercompany transactions and balances have been eliminated in consolidation.
Cash
The Company maintains deposits in financial institutions that may, at times, exceed amounts guaranteed by the Federal Deposit Insurance Corporation. These balances could be impacted if one or more of the financial institutions in which we deposit monies fails or is subject to other adverse conditions in the financial or credit markets. We have never experienced any losses related to these balances.
Variable Interest Entities
In accordance with ASC 810, Consolidation, the Company determines whether any legal entity in which the Company becomes involved is a variable interest entity (a “VIE”) and subject to consolidation. This determination is based on whether an entity has sufficient equity at risk to finance their activities without additional subordinated financial support from other parties or whose equity investors lack any of the characteristics of a controlling financial interest and whether the interest will absorb portions of a VIE’s expected losses or receive portions of its expected residual returns and are contractual, ownership, or pecuniary in nature and that change with changes in the fair value of the entity’s net assets. A reporting entity is the primary beneficiary of a VIE and must consolidate it when that party has a variable interest, or combination of variable interests, that provides it with a controlling financial interest. A party is deemed to have a controlling financial interest if it meets both of the power and losses/benefits criteria. The power criterion is the ability to direct the activities of the VIE that most significantly impact its economic performance. The losses/benefits criterion is the obligation to absorb losses from, or right to receive benefits from, the VIE that could potentially be significant to the VIE.
The Company determined that the LifeMD PC entity, the Company’s affiliated network of medical Professional Corporations and medical Professional Associations administratively led by LifeMD Southern Patient Medical Care, P.C., is a VIE and subject to consolidation. LifeMD PC and the Company do not have any stockholders in common. LifeMD PC is owned by licensed physicians, and the Company maintains a managed service agreement with LifeMD PC whereby we provide all non-clinical services to LifeMD PC. The Company determined that it is the primary beneficiary of LifeMD PC and must consolidate, as we have both the power to direct the activities of LifeMD PC that most significantly impact the economic performance of the entity and we have the obligation to absorb the losses. As a result, the Company presents the financial position, results of operations, and cash flows of LifeMD PC as part of the unaudited condensed consolidated financial statements of the Company. There is no non-controlling interest upon consolidation of LifeMD PC.
Total
net loss for LifeMD PC was approximately $
Use of Estimates
The Company prepares its unaudited condensed consolidated financial statements in conformity with U.S. GAAP which requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.
Revenue Recognition
The Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, when control of the promised goods or services is transferred to customers in an amount that reflects the consideration the Company expects to receive in exchange for those goods or services. The Company applies the following five-step model to recognize revenue from contracts with customers:
| 1. | Identification of the contract with a customer; |
| 2. | Identification of the performance obligations in the contract; |
| 3. | Determination of the transaction price; |
| 4. | Allocation of the transaction price to the performance obligations in the contract; and |
| 5. | Recognition of revenue when, or as, the performance obligations are satisfied. |
10
Telehealth Subscription Revenue
For the Company’s telehealth subscription arrangements, the Company provides both one-time and subscription-based access to its telehealth platform. The Company offers monthly and multi-month subscriptions dependent upon the subscriber’s enrollment selection. The Company has determined that there is one performance obligation that is delivered over time, as the Company allows the subscriber continuous access to the telehealth platform for the time period of the subscription. The telehealth platform access is a stand-ready obligation that is satisfied over the subscription period.
The
Company also offers bundled arrangements in which a subscriber receives subscription-based access to the Company’s telehealth platform
as well as prescribed medication. The Company has determined that there are two performance obligations related to these bundles: (i)
one performance obligation for the subscription-based service that is a stand-ready obligation that is satisfied over the subscription
period and (ii) one performance obligation for the prescribed medication that is delivered as of a point in time. For contracts with
multiple performance obligations, the transaction price is allocated to each performance obligation based on their relative standalone
selling prices, determined from the prices at which the Company separately sells these products and services. Revenue related to contracts
with multiple performance obligations was approximately $
Additionally, to fulfill its promise to customers for contracts that include the sale of prescription products, the Company maintains relationships with certain third-party pharmacies, which are licensed mail order pharmacies providing prescription fulfillment to the Company’s customers. The third-party pharmacies fill prescription orders for customers who have received a prescription from a LifeMD PC provider. The Company may account for prescription product revenue as the principal or agent in the arrangement with its customers depending on the agreement with the related third-party pharmacy. The following factors are evaluated to determine if the Company acts as principal or agent in the arrangement: (i) whether the Company has sole discretion in determining which pharmacy fills a customer’s prescription; (ii) whether the Company obtains control of the product; (iii) whether the Company is primarily responsible to the customer for the satisfactory fulfillment and acceptability of the order; (iv) whether the Company is responsible for refunds of the prescription medication after transfer of control to the customer; and (v) whether the Company sets all listed prices for the prescription products. Based on evaluation of these factors, the Company accounts for prescription product revenue as the agent in the arrangement with its largest third-party pharmacy provider.
Telehealth Product Revenue
For the Company’s product-based arrangements, the Company has determined that there is a single performance obligation, which is the delivery of the product. Revenue is recognized at a point in time when control transfers to the customer, which occurs upon shipment. The Company generally records sales of finished products when the customer places and pays for the order, with products fulfilled and simultaneously shipped either by the Company or a third-party fulfillment provider. When shipment does not occur concurrently with payment, revenue recognition is deferred until the product is shipped.
The Company also provides subscription-based arrangements involving recurring shipments of products. Revenue from these recurring product shipments is recognized at the time each shipment obligation is fulfilled.
Provisions for discounts, returns, allowances, customer rebates, and similar adjustments are recorded as reductions to gross revenue in the same period in which related sales are recognized. Discounts and rebates are known at the time of sale, while estimates for returns and allowances are based on historical data and applied consistently across the Company’s product portfolio.
Customer
discounts, returns and rebates on telehealth subscription and product revenues approximated $
11
WorkSimpli Revenue
The
Company, through its majority-owned subsidiary WorkSimpli, offers a subscription-based service providing a suite of software applications
to its subscribers, principally on a monthly subscription basis. The software suite allows the subscriber to convert almost any type
of document to another electronic form of editable document, providing ease of editing. For these subscription-based contracts with customers,
the Company offers an initial 14-day trial period which is billed at $
Collaboration Revenue
On
December 11, 2023, the Company entered into a collaboration with Medifast, Inc. through and with certain of its wholly-owned subsidiaries
(“Medifast”). Pursuant to certain agreements between the parties, Medifast agreed to pay to the Company the amount of $
The
Company determined the transaction price totaled $
For the three and nine months ended September 30, 2025 and 2024, the Company had the following disaggregated revenue:
SCHEDULE OF DISAGGREGATED REVENUE
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||||||||||||||||||
| 2025 | % | 2024 | % | 2025 | % | 2024 | % | |||||||||||||||||||||||||
| Telehealth subscription revenue | $ | % | $ | % | $ | % | $ | % | ||||||||||||||||||||||||
| Telehealth product revenue | % | % | % | % | ||||||||||||||||||||||||||||
| WorkSimpli revenue | % | % | % | % | ||||||||||||||||||||||||||||
| Medifast collaboration revenue | - | - | % | - | - | % | - | - | % | % | ||||||||||||||||||||||
| Total revenues, net | $ | % | $ | % | $ | % | $ | % | ||||||||||||||||||||||||
Deferred Revenues
The
Company records deferred revenues when cash payments are received or due in advance of its performance. As of September 30, 2025 and
December 31, 2024, the Company has accrued contract liabilities, as deferred revenue, of approximately $
The
amount of revenue recognized during the nine months ended September 30, 2025, that was included in the deferred revenue balance as of
December 31, 2024, was $
The following table summarizes deferred revenue activities for the periods presented:
SCHEDULE OF CONTRACT WITH CUSTOMER LIABILITY
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Beginning of period | $ | $ | $ | $ | ||||||||||||
| Additions | ||||||||||||||||
| Revenue recognized | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| End of period | $ | $ | $ | $ | ||||||||||||
12
Leases
The Company determines if an arrangement is a lease at inception. Operating lease right-of-use (“ROU”) assets are included in right-of-use assets on the unaudited condensed consolidated balance sheets. The current and long-term components of operating lease liabilities are included in the current operating lease liabilities and noncurrent operating lease liabilities, respectively, on the unaudited condensed consolidated balance sheets.
Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term. As most of the Company’s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at the commencement date in determining the present value of future payments. Certain leases may include options to extend or terminate the lease. Lease expense for minimum lease payments is recognized on a straight-line basis over the lease term. Leases with an initial term of 12 months or less are not recorded in the balance sheet.
Accounts Receivable, net
Accounts
receivable principally consist of payments due from merchant processors for the settlement of credit card transactions with customers.
The merchant accounts receivable balance represents the charges processed by the merchants that have not yet been deposited with the
Company. The unsettled merchant receivable amount normally represents processed sale transactions from the final one to three days of
the month, with collections being made by the Company within the first week of the following month. Management determines the need, if
any, for an allowance for future credits to be granted to customers, by regularly evaluating aggregate customer refund activity, coupled
with the consideration and current economic conditions in its evaluation of an allowance for future refunds and chargebacks. As of September
30, 2025 and December 31, 2024, the reserve for sales returns and allowances was approximately $
The Company’s accounts receivable balances are as follows for each of the periods presented:
SCHEDULE OF ACCOUNTS RECEIVABLE
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Beginning of period | $ | $ | ||||||
| End of period | $ | $ | ||||||
Inventory
As of September 30, 2025 and December 31, 2024, inventory primarily consisted of finished goods, raw materials and packaging related to the Company’s OTC products included in the telehealth product revenue section of the table above. Inventory is maintained at the Company’s third-party warehouse location in Wyoming and at various Amazon fulfillment centers. The Company also maintains inventory at a company owned warehouse in Pennsylvania.
Inventory
is valued at the lower of cost or net realizable value with cost determined on an average cost basis. Management compares the cost of
inventory with the net realizable value and an allowance is made for writing down inventory to net realizable, if lower. As of September
30, 2025 and December 31, 2024, the Company recorded an inventory reserve of approximately $
As of September 30, 2025 and December 31, 2024, the Company’s inventory consisted of the following:
SUMMARY OF INVENTORY
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Finished goods | $ | $ | ||||||
| Raw materials and packaging components | ||||||||
| Inventory reserve | ( | ) | ( | ) | ||||
| Total inventory, net | $ | $ | ||||||
Product Deposit
Many
of our vendors require deposits when a purchase order is placed for goods or fulfillment services. These deposits typically range from
13
Capitalized Software Costs
The
Company capitalizes certain internal payroll costs and third-party costs related to internally developed software and amortizes these
costs using the straight-line method over the estimated useful life of the software, generally three years. The Company does not sell
internally developed software other than through the use of subscription service. Certain development costs not meeting the criteria
for capitalization, in accordance with ASC 350-40, Internal-Use Software, are expensed as incurred. As of September 30, 2025 and
December 31, 2024, the Company capitalized a net amount of $
Intangible Assets
Intangible
assets are comprised of: (1) the ResumeBuild brand, (2) a customer relationship asset, (3) the Cleared Technologies, PBC (“Cleared”)
trade name, (4) Cleared developed technology, (5) a purchased license, (6) four purchased domain names and (7) the Optimal Human Health
MD (“OHHMD”) brand. Intangible assets are amortized over their estimated lives using the straight-line method. Costs incurred
to renew or extend the term of recognized intangible assets are capitalized and amortized over the useful life of the asset which typically
range from
Impairment of Long-Lived Assets
Long-lived assets include equipment and capitalized software. Long-lived assets are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. If such assets are considered to be impaired, an impairment is recognized as the amount by which the carrying amount of the assets exceeds the estimated fair values of the assets. As of September 30, 2025 and December 31, 2024, the Company determined that no events or changes in circumstances existed that would indicate any impairment of its long-lived assets.
Income Taxes
The Company files corporate federal, state, and local tax returns. WorkSimpli files a tax return in Puerto Rico. The Company records current and deferred taxes in accordance with ASC 740, Accounting for Income Taxes. ASC 740 requires recognition of deferred tax assets and liabilities for temporary differences between tax basis of assets and liabilities and the amounts at which they are carried in the financial statements, based upon the enacted rates in effect for the year in which the differences are expected to reverse. The Company establishes a valuation allowance when necessary to reduce deferred tax assets to the amount expected to be realized. The Company periodically assesses the value of its deferred tax asset, a majority of which has been generated by a history of net operating losses. Management determines the necessity for a valuation allowance. ASC 740 also provides a recognition threshold and measurement attribute for the financial statement recognition of a tax position taken or expected to be taken in a tax return. Using this guidance, a company may recognize the tax benefit from an uncertain tax position in its financial statements only if it is more likely-than-not (i.e., a likelihood of more than 50%) that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. The tax benefits recognized in the financial statements from such a position would be measured based on the largest benefit that has a greater than 50% likelihood of being realized upon ultimate settlement. The Company’s tax returns for all years since December 31, 2021, remain open to audit by all related taxing authorities. The Company has net operating loss carryforwards for federal income tax reporting purposes that may be applied against current and future taxable income. All remaining net operating loss carryforwards were generated after 2017 and can be carried forward indefinitely. The Company has fully reserved the deferred tax asset resulting from available net operating loss carryforwards.
Stock-Based Compensation
The Company follows the provisions of ASC 718, Share-Based Payment. Under this guidance compensation cost generally is recognized at fair value on the date of the grant and amortized over the respective vesting or service period. The fair value of options at the date of grant is estimated using the Black-Scholes option pricing model. The expected option life is derived from assumed exercise rates based upon historical exercise patterns and represents the period of time that options granted are expected to be outstanding. The expected volatility is based upon historical volatility of the Company’s common shares using daily price observations over an observation period that approximates the expected life of the options. The risk-free interest rate approximates the U.S. Treasury yield curve rate in effect at the time of grant for periods similar to the expected option life. Due to limited history of forfeitures, the Company has elected to account for forfeitures as they occur.
14
Segment Data
Our portfolio of brands are included within two operating segments: Telehealth and WorkSimpli. We believe our current segments and brands within our segments complement one another and position us well for future growth. The Company’s Chief Executive Officer is the chief operating decision maker (“CODM”) and is responsible for reviewing segment operating results to make determinations about resources to be allocated and to assess performance. Other factors, including type of business, revenue recognition and operating results are reviewed in determining the Company’s operating segments.
Fair Value of Financial Instruments
The fair value of a financial instrument is based on the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Assets and liabilities subject to ongoing fair value measurement are categorized and disclosed into one of the three categories depending on observable or unobservable inputs employed in the measurement. Hierarchical levels, which are directly related to the amount of subjectivity associated with the inputs to the valuation of these assets or liabilities, are as follows:
| 1. | Level 1: Inputs that are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. | |
| 2. | Level 2: Inputs (other than quoted prices included in Level 1) that are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. | |
| 3. | Level 3: Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities and that reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. |
In some circumstances, the inputs used to measure fair value might be categorized within different levels of the fair value hierarchy. In those instances, the fair value measurement is categorized in its entirety in the fair value hierarchy based on the lowest level input that is significant to the fair value measurement.
The fair value of the Company’s money market account is valued using Level 1 inputs. The carrying value of the Company’s financial instruments, including cash, accounts receivable, accounts payable, accrued expenses, and the face amount of notes payable and convertible long-term debt approximate fair value for all periods presented.
Concentrations of Risk
We
are dependent on certain third-party manufacturers and pharmacies for fulfillment services, prescription medications, packaging, and
finished goods. We believe that other contract manufacturers or third-party pharmacies could be quickly secured if any of our current
manufacturers or pharmacies cease to perform adequately. As of September 30, 2025, one third-party pharmacy supplied
Recent Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve its income tax disclosure requirements. Under ASU 2023-09, entities must annually: (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact this guidance will have on the disclosures in the consolidated financial statements.
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) to improve the disclosures about a public business entity’s expenses and provide more detailed information about the types of expenses included in certain expense captions in the consolidated financial statements. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this update should be applied either prospectively or retrospectively. The Company is currently evaluating the impact this guidance will have on the disclosures in the consolidated financial statements.
In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to simplify and modernize the accounting for internal-use software costs. The amendments remove references to prescriptive software development stages and clarify that capitalization of eligible software development costs begins when management authorizes and commits to funding the project and it is probable the project will be completed, and the software will be used as intended. The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual periods. Early adoption is permitted, and the guidance may be applied prospectively, retrospectively, or using a modified approach for in-process projects. The Company is evaluating the impact this guidance will have on the consolidated financial statements and related disclosures.
All other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the unaudited condensed consolidated financial statements upon adoption.
15
NOTE 3 – REVISIONS TO PREVIOUSLY ISSUED FINANCIAL STATEMENTS
The Company is revising its previously issued financial statements to correct for: (1) errors identified associated with the calculation of revenue, deferred revenue, accounts receivable and accrued expenses and (2) previously identified out-of-period adjustments. The Company has evaluated these errors in accordance with ASC 650-10-S99 and S55 (formerly Staff Accounting Bulletins (“SAB”) No. 99 and No. 108), Accounting Changes and Error Corrections.
During
the three months ended September 30, 2025, the Company identified errors related to the recording of net revenue as agent in certain
arrangements with the Company’s third-party pharmacy providers, which resulted in the misstatement of revenue in its
previously issued 2023, 2024 annual and interim financial statements and its previously issued 2025 interim financial statements.
Although the Company has determined such errors to be immaterial to its previously issued financial statements, the Company has
revised its previously issued financial statements to correct these errors. The cumulative impact of such errors for periods prior
to 2024 of $
In
addition, the Company previously identified various out-of-period amounts included in its previously issued financial statements
that were deemed to be quantitatively and qualitatively immaterial, individually and in the aggregate, to the financial statements
in the periods recorded or to the relevant prior periods. Accordingly, the Company corrected these errors in its financial
statements in the periods that the errors were identified. The Company is revising its previously issued financial statements to
correct for these errors in the appropriate prior periods. The
immaterial errors consist of:
The Company will effect such revisions to its consolidated balance sheet as of December 31, 2024 and its consolidated statement of operations, consolidated statement of changes in stockholders’ equity (deficit) and consolidated statement of cash flows for the year ended December 31, 2024 in connection with the future filing of its 2025 Annual Report on Form 10-K, which contain this comparative period and will effect the revisions for the three months ended March 31, 2025 and the three and six months ended June 30, 2025 in connection with the future filings of its Form 10-Q which contain these comparative periods. The following tables present the effect of the revisions on the financial statements previously issued as of and for the year ended December 31, 2024, for the three months ended September 30, 2024, as of and for the nine months ended September 30, 2024, as of and for the three months ended March 31, 2025, for the three months ended June 30, 2025 and as of and for the six months ended June 30, 2025 as a result of the error corrections described above:
SCHEDULE OF REVISION ON THE PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL STATEMENTS
As Previously Reported | Adjustment | As Revised | ||||||||||
| As of and for the Year Ended December 31, 2024 | ||||||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Consolidated Balance Sheet: | ||||||||||||
| Accounts receivable | $ | $ | $ | |||||||||
| Other current assets | $ | $ | $ | |||||||||
| Total Current Assets | $ | $ | $ | |||||||||
| Total Assets | $ | $ | $ | |||||||||
| Accrued expenses | $ | $ | $ | |||||||||
| Deferred revenue | $ | $ | $ | |||||||||
| Total Current Liabilities | $ | $ | $ | |||||||||
| Total Liabilities | $ | $ | $ | |||||||||
| Accumulated deficit | $ | $ | $ | |||||||||
| Total LifeMD, Inc. Stockholders’ Deficit | $ | $ | $ | |||||||||
| Non-controlling interest | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Total Stockholders’ Deficit | $ | $ | $ | |||||||||
| Total Liabilities, Mezzanine Equity and Stockholder’s Deficit | $ | $ | $ | |||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Consolidated Statement of Operations: | ||||||||||||
| Telehealth revenue, net | $ | $ | ( | ) | $ | |||||||
| Total revenues, net | $ | $ | ( | ) | $ | |||||||
| Gross profit | $ | $ | ( | ) | $ | |||||||
| General and administrative expenses | $ | $ | ( | ) | $ | |||||||
| Total expenses | $ | $ | ( | ) | $ | |||||||
| Operating loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Loss from operations before income taxes | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Net income attributable to noncontrolling interests | $ | $ | $ | |||||||||
| Net loss attributable to LifeMD, Inc. | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Basic loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Consolidated Statement of Changes in Stockholders’ Equity (Deficit): | ||||||||||||
| Accumulated deficit | $ | $ | $ | |||||||||
| Non-controlling interest | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Consolidated Statement of Cash Flows: | ||||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Accounts receivable | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Other current assets | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Deferred revenue | $ | $ | $ | |||||||||
| Accrued expenses | $ | $ | $ | |||||||||
| Net cash provided by operating activities | $ | $ | - | $ | ||||||||
16
As Previously Reported | Adjustment | As Revised | ||||||||||
| For the Three Months Ended September 30, 2024 | ||||||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Condensed Consolidated Statement of Operations: | ||||||||||||
| Telehealth revenue, net | $ | $ | ( | ) | $ | |||||||
| Total revenues, net | $ | $ | ( | ) | $ | |||||||
| Gross profit | $ | $ | ( | ) | $ | |||||||
| General and administrative expenses | $ | $ | ( | ) | $ | |||||||
| Total expenses | $ | $ | ( | ) | $ | |||||||
| Operating loss | $ | ( | ) | $ | $ | ( | ) | |||||
| Loss from operations before income taxes | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss attributable to non-controlling interests | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss attributable to LifeMD, Inc. | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
| Basic loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| As of and for the Nine Months Ended September 30, 2024 | ||||||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Condensed Consolidated Statement of Operations: | ||||||||||||
| Telehealth revenue, net | $ | $ | $ | |||||||||
| Total revenues, net | $ | $ | $ | |||||||||
| Gross profit | $ | $ | $ | |||||||||
| General and administrative expenses | $ | $ | ( | ) | $ | |||||||
| Total expenses | $ | $ | ( | ) | $ | |||||||
| Operating loss | $ | ( | ) | $ | $ | ( | ) | |||||
| Loss from operations before income taxes | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss | $ | ( | ) | $ | $ | ( | ) | |||||
| Net (loss) income attributable to noncontrolling interests | $ | ( | ) | $ | $ | |||||||
| Net loss attributable to LifeMD, Inc. | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
| Basic loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
| Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): | ||||||||||||
| Accumulated deficit | $ | $ | ( | ) | $ | |||||||
| Non-controlling interest | $ | ( | ) | $ | $ | ( | ) | |||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Condensed Consolidated Statement of Cash Flows: | ||||||||||||
| Net loss | $ | ( | ) | $ | $ | ( | ) | |||||
| Accounts receivable | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Other current assets | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Deferred revenue | $ | $ | $ | |||||||||
| Accrued expenses | $ | $ | ( | ) | $ | |||||||
| Net cash provided by operating activities | $ | $ | $ | |||||||||
| Distributions to non-controlling interest | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Net cash used in financing activities | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
17
As Previously Reported | Adjustment | As Revised | ||||||||||
| As of and for the Three Months Ended March 31, 2025 | ||||||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Condensed Consolidated Statement of Operations: | ||||||||||||
| Telehealth revenue, net | $ | $ | ( | ) | $ | |||||||
| Total revenues, net | $ | $ | ( | ) | $ | |||||||
| Gross profit | $ | $ | ( | ) | $ | |||||||
| Operating income | $ | $ | ( | ) | $ | |||||||
| Net income | $ | $ | ( | ) | $ | |||||||
| Net income (loss) attributable to LifeMD, Inc. | $ | $ | ( | ) | $ | ( | ) | |||||
| Net income (loss) attributable to LifeMD, Inc. common stockholders | $ | $ | ( | ) | $ | ( | ) | |||||
| Basic earnings (loss) per share attributable to LifeMD, Inc. common stockholders | $ | $ | ( | ) | $ | ( | ) | |||||
| Diluted earnings (loss) per share attributable to LifeMD, Inc. common stockholders | $ | $ | ( | ) | $ | ( | ) | |||||
| Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): | ||||||||||||
| Accumulated deficit | $ | $ | $ | |||||||||
| Non-controlling interest | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Condensed Consolidated Statement of Cash Flows: | ||||||||||||
| Net income | $ | $ | ( | ) | $ | |||||||
| Accounts receivable | ( | ) | ( | ) | ||||||||
| Deferred revenue | ||||||||||||
| Net cash provided by operating activities | $ | $ | - | $ | ||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| For the Three Months Ended June 30, 2025 | ||||||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Condensed Consolidated Statement of Operations: | ||||||||||||
| Telehealth revenue, net | $ | $ | $ | |||||||||
| Total revenues, net | $ | $ | $ | |||||||||
| Gross profit | $ | $ | $ | |||||||||
| Operating loss | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss attributable to LifeMD, Inc. | $ | ( | ) | $ | $ | ( | ) | |||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
| Basic loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | $ | ( | ) | |||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| As of and for the Six Months Ended June 30, 2025 | ||||||||||||
As Previously Reported | Adjustment | As Revised | ||||||||||
| Condensed Consolidated Statement of Operations: | ||||||||||||
| Telehealth revenue, net | $ | $ | ( | ) | $ | |||||||
| Total revenues, net | $ | $ | ( | ) | $ | |||||||
| Gross profit | $ | $ | ( | ) | $ | |||||||
| Operating income | $ | $ | ( | ) | $ | |||||||
| Operating income (loss) | ( | ) | ||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | |||||
| Net loss attributable to LifeMD, Inc. | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Basic loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Diluted loss per share attributable to LifeMD, Inc. common stockholders | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Condensed Consolidated Statement of Changes in Stockholders’ Equity (Deficit): | ||||||||||||
| Accumulated deficit | $ | $ | $ | |||||||||
| Non-controlling interest | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Condensed Consolidated Statement of Cash Flows: | ||||||||||||
| Net income (loss) | $ | $ | ( | ) | $ | ( | ) | |||||
| Accounts receivable | $ | $ | $ | |||||||||
| Deferred revenue | $ | ( | ) | $ | ( | ) | $ | ( | ) | |||
| Accrued expenses | $ | ( | ) | $ | $ | ( | ) | |||||
| Net cash provided by operating activities | $ | $ | - | $ | ||||||||
These accompanying notes to the unaudited condensed consolidated financial statements reflect the impact of this revision.
NOTE 4 – ACQUISITIONS
On April 24, 2025, the Company closed on the OHHMD Asset Purchase Agreement (the “OHHMD APA”) with OHHMD, PLLC, a North Carolina professional limited liability company, Doug Lucas, DO, the sole member of OHHMD, and the Company’s affiliate LifeMD Southern Patient Medical Care, P.C., a Florida professional corporation (the “PC Purchaser”), whereby the Company and the PC Purchaser acquired certain intangible assets of OHHMD, a nationwide virtual care provider focused on women’s health and hormone replacement therapies. The acquisition marked the launch of the Company’s official entry into the women’s health market and establishes a scalable clinical foundation for a comprehensive virtual health program under the LifeMD brand, focused on hormone health, bone density, metabolism, and long-term wellness.
18
The
Company accounted for the OHHMD APA as an acquisition of assets as it was determined that OHHMD did not have substantive processes at
the acquisition date and, therefore, did not meet the definition of a business under ASC 805, Business Combinations. The purchase
price consisted of
In
addition, the Company agreed to make payments of up to
The future unvested shares to be issued to Dr. Doug Lucas are equity classified share-based compensation to be recognized over-time and upon achievement of certain operational milestones in accordance with ASC 718, Share-Based Payment.
NOTE 5 – INTANGIBLE ASSETS
As of September 30, 2025 and December 31, 2024, the Company has the following amounts related to amortizable intangible assets:
SCHEDULE OF INTANGIBLE ASSETS
| September 30, | December 31, | Amortizable | ||||||||
| 2025 | 2024 | Life | ||||||||
| Amortizable Intangible Assets: | ||||||||||
| ResumeBuild brand | $ | $ | ||||||||
| Customer relationship asset | ||||||||||
| Cleared trade name | ||||||||||
| Cleared developed technology | ||||||||||
| Purchased licenses | ||||||||||
| Website domain names | ||||||||||
| OHHMD brand | - | |||||||||
| Amortizable intangible assets | - | 3 years | ||||||||
| Less: accumulated amortization | ( | ) | ( | ) | ||||||
| Total intangible assets, net | $ | $ | ||||||||
The
aggregate amortization expense of the Company’s intangible assets for the three months ended September 30, 2025 and 2024 was $
NOTE 6 – ACCRUED EXPENSES
As of September 30, 2025 and December 31, 2024, the Company has the following amounts related to accrued expenses:
SCHEDULE OF ACCRUED EXPENSES
| September 30, | December 31, | |||||||
| 2025 | 2024 | |||||||
| Accrued selling and marketing expenses | $ | $ | ||||||
| Accrued compensation | ||||||||
| Accrued legal and professional fees | ||||||||
| Accrued deferred costs | ||||||||
| Sales tax payable | ||||||||
| Accrued dividends payable | ||||||||
| Other accrued expenses | ||||||||
| Total accrued expenses | $ | $ | ||||||
19
NOTE 7 – CONVERTIBLE LONG-TERM DEBT
Avenue Capital Credit Facility
As
noted in Note 1 above, on March 21, 2023, the Company entered into the Avenue Credit Agreement and the Avenue Supplement. The Avenue
Credit Agreement provides for a convertible senior secured credit facility of up to an aggregate amount of $
On
November 15, 2023, Avenue converted $
On
May 29, 2025, Avenue converted $
On
August 5, 2025, the Company paid the remaining $
Total
interest expense on convertible long-term debt, inclusive of amortization of debt discounts, amounted to approximately $
NOTE 8 – STOCKHOLDERS’ EQUITY (DEFICIT)
The
Company has authorized the issuance of up to
The
Company entered into the ATM Sales Agreement whereby the Company may offer and sell, from time to time, shares of common stock. On June
7, 2024, the Company filed the 2024 Shelf. Under the 2024 Shelf at the time of effectiveness, the Company had the ability to raise up
to $
Options and Warrants
During
the nine months ended September 30, 2025, the Company issued an aggregate of
During
the nine months ended September 30, 2025, the Company issued an aggregate of
During
the nine months ended September 30, 2025, the Company issued an aggregate of
During
the nine months ended September 30, 2025, the Company issued an aggregate of
20
Common Stock
During
the nine months ended September 30, 2025, the Company issued an aggregate of
During
the nine months ended September 30, 2025, the Company issued an aggregate of
During
the nine months ended September 30, 2025, the Company issued an aggregate of
On
May 29, 2025, Avenue converted $
Non-controlling Interest
Net
income attributed to non-controlling interest amounted to approximately $
Dividends
The
Company pays cumulative dividends on its Series A Preferred Stock, in the amount of $
SCHEDULE OF DIVIDENDS DECLARED AND PAID ON THE SERIES A PREFERRED STOCK
| Declaration Date | Record Date | Payment Date | ||
Stock Options
On
January 8, 2021, the Company approved the Company’s 2020 Equity and Incentive Plan (the “2020 Plan”). Approval of the
2020 Plan was included as Proposal 1 in the Company’s definitive proxy statement for its Special Meeting of Stockholders filed
with the Securities and Exchange Commission on December 7, 2020. The 2020 Plan is administered by the Compensation Committee of the Board
of Directors (the “Board”) and initially provided for the issuance of up to
On
June 24, 2021, at the Annual Meeting of Stockholders, the stockholders of the Company approved the amendment and restatement to the 2020
Plan, which amended the 2020 Plan to increase the maximum number of shares of the Company’s common stock available for issuance
under the 2020 Plan by
As
of September 30, 2025, the Amended 2020 Plan provided for the issuance of up to
21
The forms of award agreements to be used in connection with awards made under the Amended 2020 Plan to the Company’s executive officers and non-employee directors are:
| ● | Form of Non-Qualified Option Agreement (Non-Employee Director Awards) |
| ● | Form of Non-Qualified Option Agreement (Employee Awards); and |
| ● | Form of Restricted Stock Award Agreement. |
Previously, the Company had granted service-based stock options and performance-based stock options separate from the Amended 2020 Plan.
The following is a summary of outstanding options activity under our Amended 2020 Plan for the nine months ended September 30, 2025:
SCHEDULE OF OPTION ACTIVITY
Options Outstanding Number of Shares | Exercise Price per Share | Weighted Average Remaining Contractual Life | Weighted Average Exercise Price per Share | |||||||||||||
| Balance, December 31, 2024 | $ | | $ | |||||||||||||
| Granted | - | - | - | - | ||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Cancelled/Forfeited/Expired | ( | ) | ||||||||||||||
| Balance at September 30, 2025 | $ | $ | ||||||||||||||
| Exercisable at December 31, 2024 | $ | $ | ||||||||||||||
| Exercisable at September 30, 2025 | $ | $ | ||||||||||||||
Total
compensation expense for the Amended 2020 Plan options above was approximately $
The following is a summary of outstanding service-based options activity (prior to the establishment of our Amended 2020 Plan above) for the nine months ended September 30, 2025:
SCHEDULE OF OPTION ACTIVITY
Options Outstanding Number of Shares | Exercise Price per Share |
Weighted Average Remaining Contractual Life | Weighted Average Exercise Price per Share | |||||||||||
| Balance, December 31, 2024 | $ | $ | ||||||||||||
| Granted | ||||||||||||||
| Exercised | ( | ) | ||||||||||||
| Cancelled/Forfeited/Expired | ( | ) | ||||||||||||
| Balance at September 30, 2025 | $ | $ | ||||||||||||
| Exercisable December 31, 2024 | $ | $ | ||||||||||||
| Exercisable at September 30, 2025 | $ | $ | ||||||||||||
The
total fair value of the options granted during the nine months ended September 30, 2025 was $
22
The following is a summary of outstanding performance-based options activity for the nine months ended September 30, 2025:
SCHEDULE OF OPTION ACTIVITY
Options Outstanding Number of Shares | Exercise Price per Share | Weighted Average Remaining Contractual Life | Weighted Average Exercise Price per Share | ||||||||||
| Balance at December 31, 2024 | $ | $ | |||||||||||
| Granted | |||||||||||||
| Cancelled/Forfeited/Expired | ( | ) | |||||||||||
| Balance at September 30, 2025 | $ | $ | |||||||||||
| Exercisable December 31, 2024 | $ | $ | |||||||||||
| Exercisable at September 30, 2025 | $ | $ | |||||||||||
Total
compensation expense under the above performance-based options plan was $
RSUs and RSAs (under our Amended 2020 Plan)
The following is a summary of unvested RSUs and RSAs activity under our Amended 2020 Plan for the nine months ended September 30, 2025:
SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY
RSUs and RSAs Unvested Number of Shares | ||||
| Balance at December 31, 2024 | ||||
| Granted | ||||
| Vested | ( | ) | ||
| Cancelled/Forfeited | ( | ) | ||
| Balance at September 30, 2025 | ||||
The
total fair value of the
RSUs and RSAs (outside of our Amended 2020 Plan)
The following is a summary of unvested RSUs and RSAs activity (outside of our Amended 2020 Plan) for the nine months ended September 30, 2025:
SCHEDULE OF RESTRICTED STOCK UNIT ACTIVITY
RSUs and RSAs Unvested Number of Shares | ||||
| Balance at December 31, 2024 | ||||
| Granted | - | |||
| Vested | ( | ) | ||
| Balance at September 30, 2025 | ||||
23
Total
compensation expense for RSUs and RSAs outside of the Amended 2020 Plan was $
Warrants
The following is a summary of outstanding and exercisable warrants activity during the nine months ended September 30, 2025:
SCHEDULE OF WARRANT OUTSTANDING AND EXERCISABLE
| Warrants Outstanding Number of Shares | Exercise
Price | Weighted Average Remaining Contractual Life | Weighted
per Share | |||||||||||||
| Balance at December 31, 2024 | $ | $ | ||||||||||||||
| Exercised | ( | ) | ||||||||||||||
| Cancelled/Forfeited/Expired | - | - | - | - | ||||||||||||
| Balance at September 30, 2025 | $ | $ | ||||||||||||||
| Exercisable December 31, 2024 | $ | $ | ||||||||||||||
| Exercisable September 30, 2025 | $ | $ | ||||||||||||||
Total
compensation expense on the above warrants for services was $
Stock-based Compensation
The
total stock-based compensation expense related to common stock granted for service-based stock options, performance-based stock options,
warrants, RSUs and RSAs amounted to approximately $
NOTE 9 – EARNINGS (LOSS) PER SHARE
Basic earnings (loss) per common share (“EPS”) is based on the weighted average number of common shares outstanding during each period presented. Shares of unissued vested restricted stock units (“RSUs”) and restricted stock awards (“RSAs”) are included in our calculation of basic weighted average common shares outstanding. Unvested RSUs and RSAs, convertible securities, warrants and options to purchase common stock are included as common stock equivalents only when dilutive. Potential common stock equivalents are excluded from diluted earnings per share when the effects would be antidilutive.
The Company follows the provisions of ASC 260, Diluted Earnings per Share. In computing diluted EPS, basic EPS is adjusted for the assumed issuance of all potentially dilutive securities. The dilutive effect of call options, warrants and share-based payment awards is calculated using the “treasury stock method,” which assumes that the “proceeds” from the exercise of these instruments are used to purchase common shares at the average market price for the period. The dilutive effect of traditional convertible debt and convertible preferred stock is calculated using the “if-converted method.” Under the if-converted method, securities are assumed to be converted at the beginning of the period, and the resulting common shares are included in the denominator of the diluted EPS calculation for the entire period being presented.
Basic loss per share is the same as diluted net loss per share attributable to common stockholders for the three and nine months ended September 30, 2025 and 2024, because the inclusion of potential shares of common stock would have been anti-dilutive. The following table discloses the securities that were not included in the computation of diluted net earnings (loss) per share as their inclusion would have been anti-dilutive:
SCHEDULE OF POTENTIALLY DILUTIVE SECURITIES
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| RSUs and RSAs | ||||||||||||||||
| Stock options | ||||||||||||||||
| Warrants | ||||||||||||||||
| Convertible long-term debt | - | |||||||||||||||
| Total | ||||||||||||||||
24
NOTE 10 – LEASES
The Company leases office spaces domestically under operating leases including: (1) the Company’s headquarters in New York, New York for which the lease expires in 2028, (2) a marketing and sales center in Huntington Beach, California for which the lease expires in 2027, (3) a patient care center in Greenville, South Carolina for which the lease expires in 2032, with an additional five year option to extend, for which the Company expects to utilize, and (4) a warehouse and pharmacy operations center in Lancaster, Pennsylvania for which the lease expires in 2029, with an additional five year option to extend, for which the Company expects to utilize. WorkSimpli leases two office spaces in Puerto Rico for which the leases expire in 2026.
The following is a summary of the Company’s operating right-of-use assets and operating lease liabilities as of September 30, 2025:
SCHEDULE OF OPERATING RIGHT OF USE OF ASSETS
| Right-of-use assets | $ | |||
| Current operating lease liabilities | $ | |||
| Noncurrent operating lease liabilities | $ |
The table below reconciles the undiscounted future minimum lease payments under the above noted operating leases to the total operating lease liabilities recognized on the unaudited condensed consolidated balance sheet as of September 30, 2025:
SCHEDULE OF MATURITY OF OPERATING LEASE LIABILITIES
| Fiscal year 2025 | $ | |||
| Fiscal year 2026 | ||||
| Fiscal year 2027 | ||||
| Fiscal year 2028 | ||||
| Fiscal year 2029 | ||||
| Thereafter | ||||
| Less: imputed interest | ( | ) | ||
| Present value of operating lease liabilities | $ |
Operating
lease expenses were approximately $
Supplemental cash flow information related to operating lease liabilities consisted of the following:
SCHEDULE OF CASH FLOW INFORMATION RELATED TO OPERATING LEASE LIABILITIES
| September 30, | ||||||||
| 2025 | 2024 | |||||||
| Cash paid for operating lease liabilities | $ | $ | ||||||
Supplemental balance sheet information related to operating lease liabilities consisted of the following:
| September
30, 2025 | December
31, 2024 | |||||||
| Weighted average remaining lease term in years | ||||||||
| Weighted average discount rate | % | % | ||||||
Additionally,
the Company utilizes office space in Puerto Rico on a month-to-month basis incurring rental expense of approximately $
NOTE 11 - COMMITMENTS AND CONTINGENCIES
Purchase Commitments
Many
of the Company’s vendors require product deposits when a purchase order is placed for goods or fulfillment services related to
inventory requirements. The Company’s history of product deposits with its inventory vendors, creates an implicit purchase commitment
equaling the total expected product acceptance cost in excess of the product deposit. As of September 30, 2025, the Company approximates
its implicit purchase commitments to be $
25
Legal Matters
In the normal course of business operations, the Company may become involved in various legal matters. As of September 30, 2025, other than as set forth below, the Company’s management does not believe that there are any potential legal matters that could have a material adverse effect on the Company’s consolidated financial position.
On August 27, 2025, a purported shareholder filed a putative class action complaint in the United States District Court for the Eastern District of New York (“EDNY”) against the Company, the Company’s Chief Executive Officer, Mr. Schreiber, and the Company’s Chief Financial Officer, Mr. Benathen, (collectively, the “Defendants”), captioned Johnston v. LifeMD, Inc., et al., Case No. 25-cv-04761, alleging: (i) violations of Section 10(b) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) and Rule 10b-5 promulgated thereunder by the Defendants for making false and misleading statements; and (ii) violations of Section 20(a) of the Exchange Act by the individual officer defendants as alleged control persons. On October 24, 2025, the EDNY granted the joint motion to transfer the class action complaint from the EDNY to the United States District Court for the Southern District of New York (“SDNY”). On October 27, 2025, the plaintiffs filed motions to be appointed lead plaintiff. The Company intends to defend vigorously against the class action.
In the months following filing of the class action complaint, four putative shareholder derivative complaints were filed, captioned: (i) Greenberg v. Schreiber et al., Case No. 25-cv-5075 (EDNY), (ii) Poulos v. Schreiber et al., Case No. 25-cv-5197 (EDNY), (iii) Shibata v. Schreiber et al., Case No. 25-cv-5284-JMW (EDNY) and (iv) Ellis v. Schreiber, et al. 125-cv-09343 (SDNY). These complaints alleged violations of Section 14(a) of the Exchange Act, breach of fiduciary duties, aiding and abetting breaches of fiduciary duties, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of Exchange Act Sections 10(b) and 21D by the Company’s officers and directors. The shareholder derivative complaints are based primarily on the same alleged conduct underlying the class action complaint described above, and seek damages in an unspecified amount and other relief. While the Company does not believe that any of the class action or shareholder derivative complaints will have a material adverse effect on the Company’s business, results of operations and financial condition, failure to obtain a favorable resolution of these complaints could have such a material adverse effect.
On
August 23, 2023, a purported putative class action complaint captioned Marden v. LifeMD, Inc., Case No. 23-cv-07469, was filed in the
United States District Court for the Southern District of New York (the “Marden Complaint”) against the Company’s RexMD
brand. The Marden Complaint alleges, inter alia, unauthorized disclosure of certain information of class members to third parties. On
November 21, 2023, the plaintiffs amended the Marden Complaint. On March 4, 2024, the Company moved to dismiss the Marden Complaint.
On July 12, 2024, the parties attended a mediation. On November 1, 2024, the plaintiffs filed a notice of voluntary dismissal of the
Southern District of New York case and on November 25, 2024, the plaintiffs refiled the case via a new complaint captioned W.M.F. &
Matthew Marden v. LifeMD, Inc., Case No. A-24-906800-C, in the District Court of Clark County, Nevada. On June 4, 2025, the Court approved
a preliminary class action settlement. On September 30, 2025, the final approval hearing for the settlement was held, and the settlement
was formally approved by the Court, certifying the class for settlement purposes and dismissing the case with prejudice. The Company
recorded approximately $
On
September 5, 2023, the Internal Revenue Service (the “IRS”) issued a notice of deficiency to the Company in which the IRS
asserted an income tax deficiency of approximately $
NOTE 12 – RELATED PARTY TRANSACTIONS
WorkSimpli Software
During
the nine months ended September 30, 2025 and 2024, the Company utilized CloudBoson Technologies Pvt. Ltd.
(“CloudBoson”), formerly LegalSubmit Pvt. Ltd. (“LegalSubmit”), a company owned by WorkSimpli’s Chief
Software Engineer, to provide software development services. The Company paid CloudBoson a total of approximately $
Legal Services
During
the nine months ended September 30, 2024, the Company utilized King & Spalding LLP (“King & Spalding”),
a large international law firm, for which an immediate family member of Robert Jindal, one of the Company’s former directors, is
the Company’s relationship partner, to provide legal services. King & Spalding ceased to be a related party of the Company
on December 18, 2024. The Company paid King & Spalding a total of approximately $
26
Consulting Agreements
On
May 30, 2023, Will Febbo, a member of the Board, entered into a consulting services agreement with the Company, pursuant to which he
provides certain investor relations and strategic business development services, in consideration for
On
June 14, 2023, Naveen Bhatia, a former member of the Board, entered into a consulting services agreement with the Company, pursuant to
which Mr. Bhatia provided certain investor relations and strategic business development services, in consideration for
Employment Agreement
Effective
May 1, 2024, Brian Schreiber, Logistics & Fulfillment Advisor, and a relative of the Company’s Chief Executive Officer, entered
into an amended employment agreement. Mr. Schreiber’s compensation package was adjusted to reflect the increased scope of his responsibilities.
The compensation adjustment, approved by the Compensation Committee of the Board, includes an annual base salary increase to $
On
July 15, 2025, the Company entered into an amendment to the bonus agreement with Mr. Schreiber dated August 16, 2017. The amendment modifies
the performance-based vesting conditions of a previously granted stock option award for
NOTE 13 – INCOME TAXES
Due to the Company’s losses and full valuation allowance, a discrete calculation was prepared for the nine month period ended September 30, 2025.
The
current income tax expense for the nine months ended September 30, 2025 was approximately $
Deferred tax assets and liabilities are recognized for temporary differences between the financial reporting basis and tax basis of assets and liabilities. Management evaluates the realizability of deferred tax assets and maintains a valuation allowance as appropriate. There have been no significant changes in uncertain tax positions during the three and nine months ended September 30, 2025.
On July 4, 2025, the One Big Beautiful Bill Act (the “OBBBA”) was enacted in the United States. The OBBBA includes several changes to federal tax law that generally allow for more favorable deductibility of certain business expenses beginning in 2025, including the restoration of immediate expensing of domestic R&D expenditures, reinstatement of 100% bonus depreciation, and more favorable rules for determining the limitation on business interest expense. The OBBBA also includes certain changes to the US taxation of foreign activity. The Company has evaluated the provisions of the OBBBA and determined that the enactment of the legislation is not expected to have a material impact on its income tax provision, net deferred tax assets or liabilities, or estimated annual effective tax rate for the three and nine months ended September 30, 2025.
27
NOTE 14 – SEGMENT DATA
Our
portfolio of brands are included within
Relevant segment data for the three and nine months ended September 30, 2025 and 2024 is as follows:
SCHEDULE OF RELEVANT SEGMENT DATA
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Three
Months Ended September 30, | Nine
months Ended September 30, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Telehealth | ||||||||||||||||
| Revenue, net | $ | $ | $ | $ | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Significant Segment Expenses: | ||||||||||||||||
| Selling and marketing expenses | ||||||||||||||||
| Payroll expenses | ||||||||||||||||
| Merchant processing fees | ||||||||||||||||
| Other general and administrative expenses | ||||||||||||||||
| Other segment items(1) | ||||||||||||||||
| Segment operating loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| WorkSimpli | ||||||||||||||||
| Revenue, net | $ | $ | $ | $ | ||||||||||||
| Cost of revenue | ||||||||||||||||
| Significant Segment Expenses: | ||||||||||||||||
| Selling and marketing expenses | ||||||||||||||||
| Payroll expenses | ||||||||||||||||
| Merchant processing fees | ||||||||||||||||
| Other general and administrative expenses | ||||||||||||||||
| Other segment items(1) | ||||||||||||||||
| Segment operating income (loss) | $ | $ | ( | ) | $ | $ | ||||||||||
| Consolidated | ||||||||||||||||
| Revenue, net | $ | $ | $ | $ | ||||||||||||
| Segment operating loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| Interest expense, net | ( | ) | ( | ) | ( | ) | ( | ) | ||||||||
| Loss on debt extinguishment | ( | ) | - | ( | ) | - | ||||||||||
| Net loss | $ | ( | ) | $ | ( | ) | $ | ( | ) | $ | ( | ) | ||||
| (1) |
| Total Assets | September
30, 2025 | December
31, 2024 | ||||||
| Telehealth | $ | $ | ||||||
| WorkSimpli | ||||||||
| Consolidated | $ | $ | ||||||
| Total Assets | $ | $ | ||||||
Total
expenditures for purchases of capitalized software, equipment, and intangible assets, which are reported on the Company’s unaudited
condensed consolidated statements of cash flows totaled $
28
NOTE 15 – SUBSEQUENT EVENTS
Stock Issued for Service
In
October 2025, the Company issued
WorkSimpli Sale
On
November 4, 2025, the Company entered into and simultaneously consummated the closing of a Stock Purchase Agreement (the “Purchase
Agreement”) by and among the Company, as a Seller and Seller Representative and the other seller parties thereto (collectively,
the “Sellers”), WorkSimpli and Lion Buyer, LLC, a Delaware limited liability company (the “Purchaser”), for the
sale by the Sellers of all of their right, title, and interest in WorkSimpli, representing
The
aggregate purchase price for the units is based on an enterprise value of approximately $
29
ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Note Regarding Forward-Looking Statements
The following discussion should be read in conjunction with the financial statements and related notes contained elsewhere in this Quarterly Report on Form 10-Q. Certain statements made in this discussion are “forward-looking statements” within the meaning of 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended (the “Exchange Act”). These statements are based upon beliefs of, and information currently available to, the Company’s management as well as estimates and assumptions made by the Company’s management. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. When used herein, the words “anticipate,” “believe,” “estimate,” “expect,” “forecast,” “future,” “intend,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue” or the negative of these terms and similar expressions as they relate to the Company or the Company’s management identify forward-looking statements. Such statements reflect the current view of the Company with respect to future events and are subject to risks, uncertainties, assumptions, and other factors, including the risks relating to the Company’s business, industry, and the Company’s operations and results of operations. Should one or more of these risks or uncertainties materialize, or should the underlying assumptions prove incorrect, actual results may differ materially from those anticipated, believed, estimated, expected, intended, or planned.
Although the Company believes that the expectations reflected in the forward-looking statements are reasonable, the Company cannot guarantee future results, levels of activity, performance, or achievements. Except as required by applicable law, including the securities laws of the United States, the Company does not intend to update any of the forward-looking statements to conform these statements to actual results.
Our unaudited condensed consolidated financial statements are prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”). These accounting principles require us to make certain estimates, judgments and assumptions. We believe that the estimates, judgments and assumptions upon which we rely are reasonable based upon information available to us at the time that these estimates, judgments and assumptions are made. These estimates, judgments and assumptions can affect the reported amounts of assets and liabilities as of the date of the unaudited condensed consolidated financial statements as well as the reported amounts of revenues and expenses during the periods presented. Our unaudited condensed consolidated financial statements would be affected to the extent there are material differences between these estimates and actual results. The following discussion should be read in conjunction with our financial statements and notes thereto appearing elsewhere in this report.
Risk factors include, by way of example and without limitation:
| ● | changes in the market acceptance of our products; |
| ● | the impact of competitive products and pricing; |
| ● | our ability to successfully commercialize our products on a large enough scale to generate profitable operations; |
| ● | our ability to maintain and develop relationships with customers and suppliers; |
| ● | our ability to respond to new technological developments quickly and effectively, including applications and risks of artificial intelligence (“AI”); |
| ● | our ability to prevent, detect and remediate cybersecurity incidents; |
| ● | our ability to protect our trade secrets or other proprietary rights, operate without infringing upon the proprietary rights of others and prevent others from infringing on our proprietary rights; |
| ● | our ability to successfully acquire, develop or commercialize new products and equipment; |
| ● | our ability to collaborate successfully with other businesses and to integrate acquired businesses or new brands; |
| ● | supply chain constraints or difficulties; |
| ● | current and potential material weaknesses in our internal control over financial reporting; |
| ● | our need to raise additional funds in the future; |
| ● | our ability to successfully recruit and retain qualified personnel; |
| ● | the impact of industry regulation, including regulation of compounded medications, insurance claims, privacy and digital healthcare; |
| ● | general economic and business conditions, including inflation, slower growth or recession; |
| ● | changes in the political or regulatory conditions in the markets in which we operate; and |
| ● | business interruptions resulting from geo-political actions, including war, and terrorism or disease outbreaks. |
Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, or performance. Readers are urged to carefully review and consider the various disclosures made by us in this report and in our other reports filed with the Securities and Exchange Commission (“SEC”). We undertake no obligation to update or revise forward-looking statements to reflect changed assumptions, the occurrence of unanticipated events or changes in the future operating results over time except as required by law. We believe that our assumptions are based upon reasonable data derived from and known about our business and operations. No assurances are made that actual results of operations or the results of our future activities will not differ materially from our assumptions.
30
Business Overview
We are a direct-to-patient telehealth company providing a high-quality, cost-effective, and convenient way to access comprehensive, virtual and in-home healthcare. We believe the traditional model of visiting a doctor’s office, traveling to a retail pharmacy, and returning for follow-up care or prescription refills is complex, inefficient, and costly which discourages many individuals from seeking much-needed medical care. LifeMD is improving the delivery of the healthcare experience through telehealth with our proprietary technology platform, affiliated and dedicated provider network, broad and expanding treatment capabilities, and the unique ability to nurture patient relationships.
The LifeMD telehealth platform integrates best-in-class capabilities including a 50-state medical group, a nationwide pharmacy network, a wholly-owned affiliated commercial pharmacy, nationwide laboratory and diagnostic testing capabilities, a fully integrated electronic medical records (“EMR”) system and a patient care and service call center. These capabilities are integrated by an industry-leading, proprietary telehealth technology that supports a broad range of primary care, chronic disease and lifestyle healthcare needs. Currently, LifeMD treats approximately 311,000 active patient subscribers across a range of their medical needs including primary care, men’s sexual health, weight management, sleep, hair loss and hormonal therapy by providing telehealth clinical services and prescription and over-the-counter (“OTC”) treatments, as medically appropriate. Our virtual primary care services are primarily offered on a subscription basis. Since inception, we have helped approximately 1,293,000 customers and patients by providing them with greater access to high-quality, convenient, and affordable care.
Our mission is to empower people to live healthier lives by increasing access to high-quality and affordable virtual and in-home healthcare. We believe our success has been, and will continue to be, attributable to an amazing patient experience, made possible by attracting and retaining the highest-quality providers in the country, and our vertically integrated care platform. As we continue to pursue long-term growth, we plan to continue to introduce new telehealth product and service offerings that complement our already expansive treatment areas.
In June 2024, the Company launched the acceptance of private health insurance for its virtual primary care services, including weight management for medically qualified patients. Initially available in select states, the Company plans to continue enrollments with private payors to facilitate access to medically necessary services, ultimately having broad coverage options across all 50 states. In April 2025, the Company expanded acceptance of insurance to Medicare beneficiaries for qualifying care. Initially available to more than 21 million Medicare Part B beneficiaries in 26 states, the Company expects to expand access to medically necessary services for more than 60 million Medicare beneficiaries nationwide, with access to qualifying services across 49 states.
Our telehealth revenue increased 34% for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024. Total revenue from recurring subscriptions is approximately 95%. In addition to our telehealth business, we owned 73.3% of WorkSimpli, which operates PDFSimpli, a software as a service platform for converting, signing, editing, and sharing PDF documents. WorkSimpli revenue from recurring subscriptions is 100%.
Our Platform and Business Strategy
We are a patient-centric telehealth company dedicated to delivering seamless end-to-end virtual healthcare directly to consumers and through select enterprise (“B2B”) partnerships. Our mission is facilitated by our robust technology platform that is purpose-built to seamlessly connect the various touchpoints involved in delivering complex care, including scheduling for a national provider network, an EMR system, secure synchronous and asynchronous communication, prescriptions, pharmacy and laboratory integrations, and more. Our platform enables us to deliver modern personalized health experiences and offerings through our websites and mobile applications, spanning customer discovery, purchase and connection with licensed providers, to pharmacy and OTC order fulfilment, through ongoing care. We believe that our seamless approach significantly reduces the complication, cost and time burden of healthcare, therefore incentivizing consumers to stick with our brands.
Our offerings are sold to consumers on a primarily subscription basis, thus creating a relationship-driven patient experience to bolster retention rates and recurring revenue. Our offerings range from prescription medication and OTC products fulfilled on a recurring basis, to primary care and weight management clinical services delivered by a team of dedicated medical providers. In general, our offerings seek to serve a patient throughout the lifecycle of their urgent, chronic, and lifestyle healthcare needs. As appropriate, prescription medications and OTC products are filled by our in-house mail order pharmacy or third-party pharmacy fulfilment partners, and are shipped directly to patients.
31
Our platform also includes a robust customer relationship management (“CRM”) system, and performance marketing platform that enables us to acquire and retain new patients and customers at scale by driving brand visibility through strategic media placements, influencer partnerships, and direct response advertising methods across highly visible marketing channels (i.e., national TV, streaming TV, streaming audio, YouTube, podcasts, Out of Home, print, magazines, online search, social media, and digital).
We leverage our telehealth technology platform and services across the two core areas described below:
Direct-to-Patient Telehealth Brands
We leverage our telehealth platform’s affiliated provider network, pharmacy, and EMR capabilities across our direct-to-patient telehealth brands. Our core telehealth brands LifeMD and Rex MD target largely unaddressed or underserved healthcare needs and are leading destinations in their respective treatment verticals of virtual primary care and men’s health.
| ○ | LifeMD is a telehealth brand that offers access to virtual primary care and telehealth services, offering comprehensive healthcare solutions across more than 200 conditions. This brand provides patients with access to affiliated high-quality providers for their urgent care and chronic care needs. LifeMD’s offering is a mobile-first full-service destination that provides seamless access to comprehensive virtual medical care including on-demand consultations and treatment, prescription medications, diagnostics and imaging, wellness coaching, integration with in-home tools and more. This offering is also supported by partnerships that provide our patients with benefits such as substantial discounts on lab work and a prescription discount card. LifeMD has served over 596,000 customers and patients to date.
In April 2023, we launched our rapidly growing GLP-1 Weight Management Program providing primary care, metabolic coaching, lab work and prescription services (as appropriate) to patients seeking to access a medically supported weight loss solution. Since inception, our Weight Management Program has grown exponentially to approximately 82,000 patient subscribers as of September 30, 2025, remaining at the forefront of the rapidly growing GLP-1 weight loss market, with our highly differentiated and comprehensive offering. In September 2024, we expanded our Weight Management Program with a personalized, non-GLP-1 treatment plan consisting of three oral medications – metformin, bupropion, and topiramate - which is expected to grow the program’s addressable market. | |
| As part of its commitment to increasing access to branded prescription GLP-1 medications, we have developed an electronic benefits verification program that allows patients to check pharmacy benefits verification upon enrolling in a LifeMD virtual care program. Secondly, we have partnered with an AI-powered platform that optimizes prior authorization submissions and aims to improve approval rates for patients. Thirdly, we are establishing direct integrations with branded manufacturers who are also committed to lower cost offerings. These enhancements are designed to minimize delays in care, reduce barriers to accessing brand-name medications, and ensure that a broader range of patients can benefit from LifeMD’s offerings. | ||
| ○ | Rex MD is a men’s telehealth platform brand that offers access to virtual medical treatment for a variety of men’s health needs, including erectile dysfunction, premature ejaculation and hair loss. After treatment from an affiliated licensed physician, if appropriate, one of our partner pharmacies will dispense and ship prescription medications and OTC products directly to the customer. Since Rex MD’s initial launch, it has expanded into additional indications including weight management and testosterone replacement therapy. Rex MD has served more than 668,000 customers and patients to date. | |
| ○ | ShapiroMD is a legacy brand offering access to virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and Food and Drug Administration (“FDA”) approved medical devices treating male and female hair loss through our telehealth platform. ShapiroMD is a leading destination for hair loss treatment across the United States (“U.S.”) and has served approximately 261,000 customers and patients to date. |
To support our telehealth brands, in November 2024 we announced the opening of a state-of-the-art wholly-owned affiliated commercial pharmacy, marking an important milestone in creating a fully integrated, end-to-end telehealth platform. This 22,500-square-foot facility, located in Lancaster, PA and designed to fill up to 5,000 daily prescriptions, allows us to offer patients a more cohesive care journey for relevant conditions from initial consultation to prescription fulfillment within a single integrated ecosystem. In September 2025, we expanded our pharmacy to include advanced non-sterile compounding capabilities for oral and topical medications, so that we could deliver tailored therapies designed to meet evolving patient needs while improving efficiency and reducing reliance on third-party providers.
B2B Telehealth Partnerships
Organizations selling healthcare products face a challenging commercial landscape. Increased competition, shrinking market sizes, and challenges reaching patients via the traditional brick-and-mortar physician offices are forcing pharmaceutical, medical device, and diagnostic companies to rethink their commercial strategies and increase their focus on digital patient awareness and engagement initiatives. It is estimated that spending on digital solutions to facilitate greater access to end markets accounts for one-third of the collective $30 billion commercial spend by these companies in the U.S. We believe LifeMD’s unique telehealth technology platform and virtual care expertise is well-positioned to address the unmet needs of healthcare product companies as they relate to digital patient awareness, access to care, adherence, and compliance.
32
During the nine months ended September 30, 2025, LifeMD executed its integration with LillyDirect’s (“Lilly”) pharmacy provider, Gifthealth, to offer streamlined access of single-dose vials of Lilly’s prescription obesity treatment Zepbound® (tirzepatide) to the Company’s eligible patients. LifeMD also announced plans to offer a simplified pathway for cash-pay patients to access all FDA-approved dose strengths of Wegovy® directly within LifeMD’s virtual care platform and an additional offering through its collaboration with Novo Nordisk that provides access to Ozempic® for patients with type 2 diabetes.
Majority Owned Subsidiary: WorkSimpli
WorkSimpli is a leading provider of workplace and document services for consumers, gig workers, and small businesses. WorkSimpli operates the following brands: (1) PDFSimpli, an online software as a service platform that allows users to create, edit, convert, sign, and share PDF documents, (2) ResumeBuild, a leading provider of digital resume and cover letter services, (3) SignSimpli, a digital signature platform and (4) LegalSimpli, a provider of legal forms for consumers and small businesses. As a result of a series of restructuring transactions, the Company’s ownership interest in WorkSimpli was 73.3%. WorkSimpli had approximately 141,000 active subscriptions as of September 30, 2025.
On November 4, 2025, we sold our majority ownership interest in WorkSimpli to Lion Buyer, LLC. The sale positions the Company as a pure-play telehealth technology company focused on scaling its virtual care and pharmacy operations. For a description of the transaction, see Note 15—Subsequent Events.
Results of Operations
During the three months ended September 30, 2025, the Company identified and corrected errors related to the recording of net revenue as agent in certain arrangements with the Company’s third-party pharmacy providers as well as various out-of-period amounts included in our previously issued financial statements that were deemed to be quantitatively and qualitatively immaterial, individually and in the aggregate, to the financial statements in the periods recorded or to the relevant prior periods. Information presented in the tables below for the three and nine months ended September 30, 2024 has been revised to reflect these corrections. See Note 3—Revisions to Previously Issued Financial Statements.
Comparison of the Three Months Ended September 30, 2025 to the Three Months Ended September 30, 2024
Our financial results for the three months ended September 30, 2025 are summarized as follows in comparison to the three months ended September 30, 2024:
| September 30, 2025 | September 30, 2024 | |||||||||||||||
| % of | % of | |||||||||||||||
| $ | Sales | $ | Sales | |||||||||||||
| Telehealth revenue, net | $ | 47,279,933 | 78,57 | % | $ | 40,154,683 | 75.38 | % | ||||||||
| WorkSimpli revenue, net | 12,892,537 | 21,43 | % | 13,117,611 | 24.62 | % | ||||||||||
| Total revenue, net | 60,172,470 | 100 | % | 53,272,294 | 100 | % | ||||||||||
| Cost of telehealth revenue | 6,714,235 | 11.16 | % | 4,300,877 | 8.07 | % | ||||||||||
| Cost of WorkSimpli revenue | 693,678 | 1.15 | % | 712,664 | 1.34 | % | ||||||||||
| Total cost of revenue | 7,407,913 | 12.31 | % | 5,013,541 | 9.41 | % | ||||||||||
| Gross profit | 52,764,557 | 87.69 | % | 48,258,753 | 90.59 | % | ||||||||||
| Selling and marketing expenses | 29,474,490 | 48.98 | % | 26,611,672 | 49.97 | % | ||||||||||
| General and administrative expenses | 16,589,390 | 27.57 | % | 18,115,143 | 34.00 | % | ||||||||||
| Customer service expenses | 2,784,320 | 4.63 | % | 2,804,210 | 5.26 | % | ||||||||||
| Other operating expenses | 3,039,135 | 5.05 | % | 2,112,169 | 3.96 | % | ||||||||||
| Development costs | 2,846,436 | 4.73 | % | 2,611,833 | 4.90 | % | ||||||||||
| Total expenses | 54,733,771 | 90.96 | % | 52,255,027 | 98.09 | % | ||||||||||
| Operating loss | (1,969,214 | ) | (3.27 | )% | (3,996,274 | ) | (7.50 | )% | ||||||||
| Interest expense, net | (262,456 | ) | (0.44 | )% | (558,597 | ) | (1.05 | )% | ||||||||
| Loss on debt extinguishment | (1,155,851 | ) | (1.92 | )% | - | - | % | |||||||||
| Net loss before income taxes | (3,387,521 | ) | (5.63 | )% | (4,554,871 | ) | (8.55 | )% | ||||||||
| Income tax expense | (169,134 | ) | (0.28 | )% | (232,523 | ) | (0.44 | )% | ||||||||
| Net loss | (3,556,655 | ) | (5.91 | )% | (4,787,394 | ) | (8.99 | )% | ||||||||
| Net income (loss) attributable to non-controlling interest | 249,462 | 0.42 | % | (129,472 | ) | (0.25 | )% | |||||||||
| Net loss attributable to LifeMD, Inc. | (3,806,117 | ) | (6.33 | )% | (4,657,922 | ) | (8.74 | )% | ||||||||
| Preferred stock dividends | (776,563 | ) | (1.29 | )% | (776,563 | ) | (1.46 | )% | ||||||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | (4,582,680 | ) | (7.62 | )% | $ | (5,434,485 | ) | (10.20 | )% | ||||||
33
Total revenue, net. Revenues for the three months ended September 30, 2025 were approximately $60.2 million, an increase of 13% compared to approximately $53.3 million for the three months ended September 30, 2024. The increase in revenues was attributable to an increase in telehealth subscription revenue, primarily for LifeMD primary care which experienced an increase of approximately $6.4 million during the three months ended September 30, 2025 compared to the three months ended September 30, 2024 primarily due to an increase in online sales demand. Telehealth revenue accounts for 79% of total revenue. WorkSimpli revenue accounts for 21% of total revenue and has decreased by approximately $225 thousand, or 2%, for the three months ended September 30, 2025 compared to the three months ended September 30, 2024, primarily due to a decrease in online sales demand.
Total cost of revenue. Total cost of revenue consists of the cost of (1) telehealth revenues, which primarily include product costs, pharmacy fulfilment costs, physician consult fees, and shipping costs directly attributable to our prescription and OTC products and (2) WorkSimpli revenue consisting primarily of information technology fees related to providing the services made available on our online platform. Total cost of revenue increased by approximately 48% to approximately $7.4 million for the three months ended September 30, 2025 compared to approximately $5.0 million for the three months ended September 30, 2024. The combined cost of revenue increase was due to increased sales volume during the three months ended September 30, 2025 when compared to the three months ended September 30, 2024. Telehealth costs increased to 14% of associated telehealth revenues experienced during the three months ended September 30, 2025, from 11% of associated telehealth revenues during the three months ended September 30, 2024 due to increases in physician consult fees and product shipping costs. WorkSimpli costs stayed consistent at 5% of associated WorkSimpli revenues for both the three month periods ended September 30, 2025 and 2024.
Gross profit. Gross profit increased by 9% to approximately $52.8 million for the three months ended September 30, 2025 compared to approximately $48.3 million for the three months ended September 30, 2024. Gross profit as a percentage of revenues was approximately 88% for the three months ended September 30, 2025 as compared to approximately 91% for the three months ended September 30, 2024. Gross profit as a percentage of revenues for telehealth was 86% for the three months ended September 30, 2025 compared to 89% for the three months ended September 30, 2024, and for WorkSimpli was 95% for both the three month periods ended September 30, 2025 and 2024. The increase in sales volume and demand for telehealth subscriptions, partially offset by the increase in physician consult fees and product shipping costs contributed to the increase in gross profit. The increase in physician consult fees and product shipping costs also contributed to the decrease in gross profit as a percentage of telehealth revenue.
Total expenses. Operating expenses for the three months ended September 30, 2025 were approximately $54.7 million, as compared to approximately $52.3 million for the three months ended September 30, 2024. This represents an increase of 5%, or approximately $2.5 million. The increase is primarily attributable to:
| (i) | Selling and marketing expenses: This mainly consists of online marketing and advertising expenses. During the three months ended September 30, 2025, the Company had an increase of approximately $2.9 million, or 11% in selling and marketing costs resulting from additional sales and marketing initiatives to drive the current period’s sales growth primarily for telehealth subscription revenue. This ramp up is expected to both increase and maintain sustained revenue growth in future years, based on the Company’s recurring revenue subscription-based sales model. |
| (ii) | Other operating expenses: This consists of rent and lease expense, insurance, office supplies and software subscriptions, royalty expense and bank charges. During the three months ended September 30, 2025, the Company had an increase of approximately $927 thousand, or 44%, primarily related to increases in software subscriptions to support the Company’s growth and compliance initiatives. |
| (iii) | Development costs: This mainly relates to third-party technology services for developing and maintaining our online platforms. During the three months ended September 30, 2025, the Company had an increase of approximately $235 thousand, or 9%, primarily resulting from technology platform improvements and amortization expenses. |
The above increases in expenses were partially offset by the following decreases in expenses:
| (i) | General and administrative expenses: This category mainly consists of stock-based compensation expense, merchant processing fees, payroll expenses for corporate employees, taxes and licenses, amortization expense and legal and professional fees. During the three months ended September 30, 2025, the Company had a decrease of approximately $1.5 million in general and administrative expenses, primarily related to a decrease in legal and professional fees of $1.2 million, a decrease in sales tax accruals of $793 thousand and a decrease in payroll costs of $446 thousand, partially offset by an increase in stock-based compensation expense of $804 thousand. |
| (ii) | Customer service expenses: This consists of rent, insurance, payroll and benefit expenses related to the Company’s patient care center in South Carolina. During the three months ended September 30, 2025, the Company had a decrease of approximately $20 thousand, or 0.7%. |
34
Interest expense, net. Interest expense, net consists of interest expense related to the Avenue Facility, partially offset by interest income on the Company’s cash account balances for the three months ended September 30, 2025 and interest expense related to the Avenue Facility and notes payable, partially offset by interest income on the Company’s cash account balances for the three months ended September 30, 2024. Interest expense decreased by approximately $296 thousand during the three months ended September 30, 2025 as compared to the three months ended September 30, 2024, primarily due to the repayment of the Avenue Facility on August 5, 2025.
Loss on debt extinguishment. The Company recorded a $1.2 million loss on debt extinguishment related to the repayment of the Avenue Facility during the three months ended September 30, 2025 due to a prepayment penalty and various fees associated with the Avenue Facility.
Comparison of the Nine Months Ended September 30, 2025 to the Nine Months Ended September 30, 2024
Our financial results for the nine months ended September 30, 2025 are summarized as follows in comparison to the nine months ended September 30, 2024:
| September 30, 2025 | September 30, 2024 | |||||||||||||||
| % of | % of | |||||||||||||||
| $ | Sales | $ | Sales | |||||||||||||
| Telehealth revenue, net | $ | 147,186,714 | 78.72 | % | $ | 109,687,054 | 73.45 | % | ||||||||
| WorkSimpli revenue, net | 39,788,325 | 21.28 | % | 39,650,009 | 26.55 | % | ||||||||||
| Total revenue, net | 186,975,039 | 100 | % | 149,337,063 | 100 | % | ||||||||||
| Cost of telehealth revenue | 21,689,400 | 11.60 | % | 13,049,315 | 8.74 | % | ||||||||||
| Cost of WorkSimpli revenue | 1,793,133 | 0.96 | % | 1,589,318 | 1.06 | % | ||||||||||
| Total cost of revenue | 23,482,533 | 12.56 | % | 14,638,633 | 9.80 | % | ||||||||||
| Gross profit | 163,492,506 | 87.44 | % | 134,698,430 | 90.20 | % | ||||||||||
| Selling and marketing expenses | 87,793,648 | 46.95 | % | 77,164,480 | 51.66 | % | ||||||||||
| General and administrative expenses | 51,210,246 | 27.39 | % | 51,160,883 | 34.26 | % | ||||||||||
| Customer service expenses | 9,086,549 | 4.86 | % | 7,385,669 | 4.95 | % | ||||||||||
| Other operating expenses | 8,582,655 | 4.59 | % | 6,318,791 | 4.23 | % | ||||||||||
| Development costs | 8,265,842 | 4.42 | % | 7,101,655 | 4.76 | % | ||||||||||
| Total expenses | 164,938,940 | 88.21 | % | 149,131,478 | 99.86 | % | ||||||||||
| Operating loss | (1,446,434 | ) | (0.77 | )% | (14,433,048 | ) | (9.66 | )% | ||||||||
| Interest expense, net | (1,551,758 | ) | (0.83 | )% | (1,567,743 | ) | (1.05 | )% | ||||||||
| Loss on debt extinguishment | (1,155,851 | ) | (0.62 | )% | - | - | % | |||||||||
| Net loss before income taxes | (4,154,043 | ) | (2.22 | )% | (16,000,791 | ) | (10.71 | )% | ||||||||
| Income tax expense | (169,134 | ) | (0.09 | )% | (232,523 | ) | (0.16 | )% | ||||||||
| Net loss | (4,323,177 | ) | (2.31 | )% | (16,233,314 | ) | (10.87 | )% | ||||||||
| Net income (loss) attributable to non-controlling interest | 1,286,382 | 0.69 | % | 237,037 | 0.16 | % | ||||||||||
| Net loss attributable to LifeMD, Inc. | (5,609,599 | ) | (3.00 | )% | (16,470,351 | ) | (11.03 | )% | ||||||||
| Preferred stock dividends | (2,329,688 | ) | (1.25 | )% | (2,329,688 | ) | (1.56 | )% | ||||||||
| Net loss attributable to LifeMD, Inc. common stockholders | $ | (7,939,247 | ) | (4.25 | )% | $ | (18,800,039 | ) | (12.59 | )% | ||||||
Total revenue, net. Revenues for the nine months ended September 30, 2025 were approximately $187.0 million, an increase of 25% compared to approximately $149.3 million for the nine months ended September 30, 2024. The increase in revenues was attributable to the increase in telehealth revenue of 34%. Telehealth revenue accounts for 79% of total revenue and has increased during the nine months ended September 30, 2025 due to an increase in telehealth subscription revenue, primarily for LifeMD primary care which experienced an increase of approximately $41.2 million during the nine months ended September 30, 2025 compared to the nine months ended September 30, 2024 due to increased demand. WorkSimpli revenue accounts for 22% of total revenue and stayed consistent for both the nine month periods ended September 30, 2025 and 2024.
35
Total cost of revenue. Total cost of revenue consists of the cost of (1) telehealth revenues, which primarily include product costs, pharmacy fulfilment costs, physician consult fees, and shipping costs directly attributable to our prescription and OTC products and (2) WorkSimpli revenue consisting primarily of information technology fees related to providing the services made available on our online platform. Total cost of revenue increased by approximately 60% to approximately $23.5 million for the nine months ended September 30, 2025 compared to approximately $14.6 million for the nine months ended September 30, 2024. The combined cost of revenue increase was due to increased sales volume during the nine months ended September 30, 2025 when compared to the nine months ended September 30, 2024. Telehealth costs increased to 15% of associated telehealth revenues experienced during the nine months ended September 30, 2025, from 12% of associated telehealth revenues during the nine months ended September 30, 2024 primarily due to increases in physician consult fees and product shipping costs. WorkSimpli costs increased to 5% of associated WorkSimpli revenues for the nine months ended September 30, 2025 as compared to 4% of associated WorkSimpli revenues for the nine months ended September 30, 2024.
Gross profit. Gross profit increased by approximately 21% to approximately $163.5 million for the nine months ended September 30, 2025 compared to approximately $134.7 million for the nine months ended September 30, 2024. Gross profit as a percentage of revenues was approximately 87% for the nine months ended September 30, 2025 as compared to approximately 90% for the nine months ended September 30, 2024. Gross profit as a percentage of revenues for telehealth was 85% for the nine months ended September 30, 2025 compared to 88% for the nine months ended September 30, 2024, and for WorkSimpli was 95% for the nine months ended September 30, 2025 compared to 96% for the nine months ended September 30, 2024. The increase in sales volume and demand for telehealth subscriptions partially offset by an increase in physician consult fees and product shipping costs, contributed to the increase in gross profit. The increase in physician consult fees and product shipping costs as well as the Medifast Collaboration revenue recognized during the nine months ended September 30, 2024 also contributed to the decrease in gross profit as a percentage of telehealth revenue for the nine months ended September 30, 2025.
Total expenses. Operating expenses for the nine months ended September 30, 2025 were approximately $164.9 million, as compared to approximately $149.1 million for the nine months ended September 30, 2024. This represents an increase of 11%, or approximately $15.8 million. The increase is primarily attributable to:
| (i) | Selling and marketing expenses: This mainly consists of online marketing and advertising expenses. During the nine months ended September 30, 2025, the Company had an increase of approximately $10.6 million, or 14% in selling and marketing costs resulting from additional sales and marketing initiatives to drive the current period’s sales growth primarily for LifeMD virtual primary care. This ramp up is expected to both increase and maintain sustained revenue growth in future years, based on the Company’s recurring revenue subscription-based sales model. |
| (ii) | General and administrative expenses: This category mainly consists of stock-based compensation expense, merchant processing fees, payroll expenses for corporate employees, taxes and licenses, amortization expense and legal and professional fees. During the nine months ended September 30, 2025, the Company had an increase of approximately $0.1 million in general and administrative expenses, primarily related to an increase in merchant processing fees of $864 thousand and an increase in payroll costs of $837 thousand partially offset by a decrease in stock-based compensation expense of $1.3 million and a decrease in legal and professional fees of $305 thousand. |
| (iii) | Customer service expenses: This consists of rent, insurance, payroll and benefit expenses related to the Company’s patient care center in South Carolina. During the nine months ended September 30, 2025, the Company had an increase of approximately $1.7 million, or 23%, primarily related to increases in infrastructure costs and compensation costs due to increased headcount to support the Company’s growth. |
| (iv) | Other operating expenses: This consists of rent and lease expense, insurance, office supplies and software subscriptions, royalty expense and bank charges. During the nine months ended September 30, 2025, the Company had an increase of approximately $2.3 million, or 36%, primarily related to increases in software subscriptions. |
| (v) | Development costs: This mainly relates to third-party technology services for developing and maintaining our online platforms. During the nine months ended September 30, 2025, the Company had an increase of approximately $1.2 million, or 16%, primarily resulting from technology platform improvements and amortization expenses. |
Interest expense, net. Interest expense, net consists of interest expense related to the Avenue Facility, partially offset by interest income on the Company’s cash account balances for the nine months ended September 30, 2025 and interest expense related to the Avenue Facility and notes payable, partially offset by interest income on the Company’s cash account balances for the nine months ended September 30, 2024. Interest expense stayed consistent for both the nine month periods ended September 30, 2025 and 2024.
Loss on debt extinguishment. The Company recorded a $1.2 million loss on debt extinguishment related to the repayment of the Avenue Facility during the nine months ended September 30, 2025 due to a prepayment penalty and various fees associated with the Avenue Facility.
36
Working Capital
| September
30, 2025 | December
31, 2024 | |||||||
| Current assets | $ | 41,085,605 | $ | 52,369,360 | ||||
| Current liabilities | 56,663,553 | 67,400,168 | ||||||
| Working capital | $ | (15,577,948 | ) | $ | (15,030,808 | ) | ||
Working capital decreased by approximately $0.5 million during the nine months ended September 30, 2025. The decrease in current assets is primarily attributable to a decrease in cash of approximately $11.2 million due to the repayment of the Avenue Facility on August 5, 2025 and a decrease in accounts receivable of approximately $1.6 million, partially offset by an increase in other current assets of approximately $0.6 million. Current liabilities decreased by approximately $10.7 million, which was primarily attributable to a decrease in current portion of long-term debt of approximately $8.4 million due to the repayment of the Avenue Facility on August 5, 2025 and a decrease in deferred revenue of $5.3 million, partially offset by an increase in accounts payable and accrued expenses of approximately $2.8 million.
Liquidity and Capital Resources
| Nine Months Ended September 30, | ||||||||
| 2025 | 2024 | |||||||
| Net cash provided by operating activities | $ | 11,560,698 | $ | 16,439,889 | ||||
| Net cash used in investing activities | (10,161,401 | ) | (8,815,591 | ) | ||||
| Net cash used in financing activities | (12,618,450 | ) | (3,183,770 | ) | ||||
| Net (decrease) increase in cash | (11,219,153 | ) | 4,440,528 | |||||
Net cash provided by operating activities was approximately $11.6 million for the nine months ended September 30, 2025, as compared with approximately $16.4 million for the nine months ended September 30, 2024. The significant factors contributing to the net cash provided by operating activities during the nine months ended September 30, 2025, include: (1) $8.7 million in non-cash depreciation and amortization, (2) $7.8 million in non-cash stock-based compensation charges, (3) an increase in accounts payable and accrued expenses of $2.8 million and (4) $1.2 million loss on debt extinguishment recorded related to the repayment of the Avenue Facility on August 5, 2025. These increases were partially offset by a decrease in deferred revenue of $5.3 million and the Company’s net loss of $4.3 million for the nine months ended September 30, 2025. The significant factors contributing to the net cash provided by operating activities during the nine months ended September 30, 2024, include: (1) an increase in accounts payable and accrued expenses of $12.4 million, (2) an increase in deferred revenue of $10.9 million, (3) $9.1 million in non-cash stock-based compensation charges, and (4) $7.3 million in non-cash depreciation and amortization. These increases were partially offset by: (1) the Company’s net loss of $16.2 million for the nine months ended September 30, 2024, (2) an increase in accounts receivable of $5.2 million and (3) an increase in other current assets of $2.3 million.
Net cash used in investing activities for the nine months ended September 30, 2025 was approximately $10.2 million, as compared with approximately $8.8 million for the nine months ended September 30, 2024. Net cash used in investing activities for the nine months ended September 30, 2025, was due to cash paid for capitalized software costs of approximately $8.4 million, and cash paid for the purchase of equipment of approximately $1.7 million. Net cash used in investing activities for the nine months ended September 30, 2024, was due to cash paid for capitalized software costs of approximately $7.5 million, and cash paid for the purchase of equipment of approximately $1.3 million.
Net cash used in financing activities for the nine months ended September 30, 2025 was approximately $12.6 million as compared with approximately $3.2 million for the nine months ended September 30, 2024. Net cash used in financing activities for the nine months ended September 30, 2025, consisted of: (1) the repayment of the Avenue Facility on August 5, 2025 of approximately $18.7 million, (2) preferred stock dividends of $2.3 million, and (3) distributions to non-controlling interest of $762 thousand partially offset by $8.7 million net proceeds received related to sales of common stock under the ATM Sales Agreement and $471 thousand of cash proceeds received from the exercise of options and warrants. Net cash used in financing activities for the nine months ended September 30, 2024, consisted of: (1) preferred stock dividends of $2.3 million, (2) distributions to non-controlling interest of $603 thousand, (3) repayments of notes payable of approximately $328 thousand, and (4) the final contingent consideration payment made related to the ResumeBuild acquisition of approximately $31 thousand, partially offset by proceeds from the exercise of options of approximately $108 thousand.
Liquidity and Capital Resources Outlook
To date, the Company has been funding operations primarily through the sales of its products, issuance of common and preferred stock, and through loans and advances. Our primary short-term and long-term requirements for liquidity and capital are for customer acquisitions, funding business acquisitions and investments we may make from time to time, working capital including our noncancelable operating lease obligations, long-term debt obligations, capital expenditures and general corporate purposes. For more information on our operating lease obligations, see Note 10—Leases to our unaudited condensed consolidated financial statements included in this report.
37
On March 21, 2023, the Company entered into and closed on a loan and security agreement (the “Avenue Credit Agreement”), and a supplement to the Credit Agreement (the “Avenue Supplement”), with Avenue Venture Opportunities Fund II, L.P. and Avenue Venture Opportunities Fund, L.P. (collectively, “Avenue”). The Avenue Credit Agreement provided for a convertible senior secured credit facility of up to an aggregate amount of $40 million, comprised of the following: (1) $15 million in term loans funded at closing, (2) $5 million of additional committed term loans which the Company received on September 26, 2023 under the First Amendment to the Avenue Credit Agreement (the “Avenue First Amendment”) and (3) $20 million of additional uncommitted term loans, collectively referred to as the “Avenue Facility”. The Company issued Avenue warrants to purchase $1.2 million of the Company’s common stock at an exercise price of $1.24, subject to adjustments, of which $660 thousand have been exercised (the “Avenue Warrants”). In addition, Avenue converted $2 million of the $15 million in term loans funded at closing into shares of the Company’s common stock at a price per share equal to $1.49. Proceeds from the Avenue Facility were used to repay the Company’s outstanding notes payable balances with CRG Financial. On August 5, 2025, the Company paid the remaining $14.0 million in outstanding principal payments on the Avenue Facility and the prepayment penalty as noted in the Avenue Credit Agreement. As of September 30, 2025, there are no principal payments remaining on the Avenue Facility. The Company recorded a loss on debt extinguishment of $1.2 million within its unaudited condensed consolidated financial statements for the three and nine months ended September 30, 2025.
The Company entered into an At Market Issuance Sales Agreement (the “ATM Sales Agreement”) with B. Riley Securities, Inc. and Cantor Fitzgerald & Co. relating to the sale of its common stock. In accordance with the terms of the ATM Sales Agreement, the Company may, but is not obligated to, offer and sell, from time to time, shares of common stock, through or to the Agents, acting as agent or principal. Sales of common stock, if any, will be made by any method permitted that is deemed an “at the market offering” as defined in Rule 415 under the Securities Act. On June 7, 2024, the Company filed a shelf registration statement on Form S-3 under the Securities Act, which was declared effective on July 18, 2024 (the “2024 Shelf”). Under the 2024 Shelf at the time of effectiveness, the Company had the ability to raise up to $150.0 million by selling common stock, preferred stock, debt securities, warrants, and units including $53.3 million of its common stock under the ATM Sales Agreement. During the three months ended September 30, 2025, the Company sold 762,990 shares of common stock under the ATM Sales Agreement and net proceeds received were $8.7 million. As of September 30, 2025, the Company had $44.6 million available under the ATM Sales Agreement.
The Company expects that its existing cash as of September 30, 2025 of $23.8 million will be sufficient to fund our planned operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of these unaudited condensed consolidated financial statements.
Critical Accounting Estimates
We prepare our unaudited condensed consolidated financial statements in accordance with U.S. generally accepted accounting principles, which require our management to make estimates that affect the reported amounts of assets, liabilities and disclosures of contingent assets and liabilities at the balance sheet dates, as well as the reported amounts of revenues and expenses during the reporting periods. To the extent that there are material differences between these estimates and actual results, our financial condition or results of operations would be affected. We base our estimates on our own historical experience and other assumptions that we believe are reasonable after taking into account our circumstances and expectations for the future based on available information. We evaluate these estimates on an ongoing basis.
We consider an accounting estimate to be critical if: (i) the accounting estimate requires us to make assumptions about matters that were highly uncertain at the time the accounting estimate was made, and (ii) changes in the estimate that are reasonably likely to occur from period to period or use of different estimates that we reasonably could have used in the current period, would have a material impact on our financial condition or results of operations. There are items within our financial statements that require estimation but are not deemed critical, as defined above.
Our significant accounting policies are more fully described in Note 2—Basis of Presentation and Summary of Significant Accounting Policies to our unaudited condensed consolidated financial statements included in this report.
Recent Accounting Pronouncements
In December 2023, the Financial Accounting Standards Board (“FASB”) issued ASU 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures, to improve its income tax disclosure requirements. Under ASU 2023-09, entities must annually: (1) disclose specific categories in the rate reconciliation and (2) provide additional information for reconciling items that meet a quantitative threshold. The amendments in this update are effective for annual periods beginning after December 15, 2024. The Company is currently evaluating the impact that ASU 2023-09 will have to its financial disclosures.
38
In November 2024, the FASB issued ASU 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40) to improve the disclosures about a public business entity’s expenses and provide more detailed information about the types of expenses included in certain expense captions in the consolidated financial statements. The amendments in this update are effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027. Early adoption is permitted and the amendments in this update should be applied either prospectively or retrospectively. The Company is evaluating the impact this guidance will have on the disclosures in the consolidated financial statements.
In September 2025, the FASB issued ASU 2025-06, Intangibles—Goodwill and Other—Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to simplify and modernize the accounting for internal-use software costs. The amendments remove references to prescriptive software development stages and clarify that capitalization of eligible software development costs begins when management authorizes and commits to funding the project and it is probable the project will be completed, and the software will be used as intended. The amendments in this update are effective for annual reporting periods beginning after December 15, 2027, and interim reporting periods within those annual periods. Early adoption is permitted, and the guidance may be applied prospectively, retrospectively, or using a modified approach for in-process projects. The Company is evaluating the impact this guidance will have on the consolidated financial statements and related disclosures.
All other accounting standards updates that have been issued or proposed by the FASB that do not require adoption until a future date are not expected to have a material impact on the consolidated financial statements upon adoption.
Item 3. Quantitative and Qualitative Disclosures about Market Risk
As a smaller reporting company, we are not required to provide the information required by this Item.
Item 4. Controls and Procedures
Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as that term is defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (the “Exchange Act”)) that are designed to provide reasonable assurance that information required to be disclosed in our reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our chief executive officer and chief financial officer, as appropriate, to allow timely decisions regarding required disclosures. In designing disclosure controls and procedures, our management is required to apply its judgment in evaluating the cost-benefit relationship of possible disclosure controls and procedures. The design of any disclosure controls and procedures also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.
Our management, with the participation of our chief executive officer and chief financial officer, has evaluated the effectiveness of our disclosure controls and procedures as of September 30, 2025. Based upon that evaluation and subject to the foregoing, our chief executive officer and chief financial officer concluded that, our disclosure controls and procedures were not effective as of such date due to the material weaknesses in internal control over financial reporting described below.
Material Weaknesses in Internal Control over Financial Reporting
As previously disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2024, we identified material weaknesses in our internal control over financial reporting related to: (i) our information technology general controls (“ITGCs”), particularly in the areas of user access, change management and computer operations within certain of our information systems and review of key third-party service provider Systems and Organizational Controls (“SOC”) reports and (ii) business process controls related to Information Produced by the Entity (“IPE”) and system generated IPE and insufficient evidence of formal review and approval procedures of key information utilized in the performance of the control. These material weaknesses did not result in a misstatement of the Company’s financial statements.
39
Additionally during the three months ended September 30, 2025, the Company identified a material weakness related to the lack of effectively designed controls related to the recording of net revenue as agent in certain arrangements with the Company’s third-party pharmacy providers. Management has concluded the material weakness existed as of December 31, 2024 and in the subsequent interim periods in 2025. The material weakness resulted in immaterial misstatements of revenue, deferred revenue, accounts receivable and accrued expenses in the 2023 annual and the Q3 and Q4 interim financial statements, the 2024 annual and interim financial statements, and the Q1 and Q2 2025 interim financial statements that resulted in the revision of the previously issued annual and interim financial statements.
Additionally, these material weaknesses could result in the misstatement of the interim or annual consolidated financial statements that would result in a material misstatement to the financial statements that would not be prevented or detected.
Management’s Plan to Remediate the Material Weaknesses
To remediate the identified material weaknesses, our management, with oversight from our audit committee, implemented a remediation plan. The Company has taken the following steps to further our remediation:
| (i) | documented and maintained evidence of the completeness and accuracy of manually generated IPE and system generated IPE and review of controls, including focused training for process owners; | |
| (ii) | formalized user access, change management and computer operations controls of our internal information systems as well as SOC report reviews for in-scope third-party systems; | |
| (iii) | implemented focused ITGC training for key system owners; | |
| (iv) | increased the frequency of user access reviews of our internal information systems; | |
| (v) | modified system reporting over revenue to increase completeness and accuracy over information used in the calculation of revenue, deferred revenue, accounts receivable and accrued expenses for customers of a specific contract; and | |
| (vi) | designing and implementing a reconciliation process over such contract reporting to ensure completeness and accuracy of information. |
We continue to evaluate and refine the design of certain key controls in the areas of user access, change management and computer operations. We may take additional measures to address control deficiencies, or we may modify certain of the remediation efforts described above.
Changes in Internal Control over Financial Reporting
As it specifically relates to (v) and (vi) above, there have been changes in our internal control over financial reporting (as defined in Rule 13a-15(f) and 15d-15(f) under the Exchange Act) during the three months ended September 30, 2025 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.
40
PART II – OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
In the ordinary course of our operations, we become involved in ordinary routine litigation incidental to the business. Material proceedings are described under Note 11, “Commitments and Contingencies” to the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q.
ITEM 1A. RISK FACTORS
An investment in the Company’s common stock involves a number of very significant risks. You should carefully consider the risk factors included in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on March 11, 2025, in addition to other information contained in our reports and in this quarterly report in evaluating the Company and its business before purchasing shares of our common stock. There have been no material changes to our risk factors contained in our Annual Report on Form 10-K for the year ended December 31, 2024. The Company’s business, operating results and financial condition could be adversely affected due to any of those risks.
ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS
The following disclosures set forth certain information with respect to all securities sold by the Company during the three months ended September 30, 2025 without registration under the Securities Act:
On July 23, 2025, July 24, 2025, August 14, 2025, and August 26, 2025, the Company issued 40,500, 49,000, 41,500 and 400,667 shares, respectively, of common stock for services, including vested restricted stock to employees and directors.
The above transactions did not involve any underwriters, underwriting discounts or commissions, or any public offering. The Company relied upon the exemption from the registration requirements of the Securities Act by virtue of Section 4(a)(2) thereof and/or Regulation D promulgated by the SEC under the Securities Act.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
None.
ITEM 4. MINE SAFETY DISCLOSURES
Not Applicable.
ITEM 5. OTHER INFORMATION
As described in Part 1, Item 4. Controls and Procedures, we have identified an additional material weakness in our internal control over financial reporting as of September 30, 2025. We have concluded that this material weakness also existed as of December 31, 2024, March 31, 2025 and June 30, 2025. Accordingly, the previous conclusion included in Item 9A of our Form 10-K filed with the Securities and Exchange Commission on March 11, 2025 that our disclosure controls and procedures and internal control over financial reporting were ineffective is hereby updated to include this additional material weakness. Also, the previous conclusions included in Item 4 of our Forms 10-Q filed with the Securities and Exchange Commission on May 6, 2025 and August 5, 2025 that our disclosure controls and procedures was ineffective is hereby updated to also include this additional material weakness.
41
ITEM 6. EXHIBITS
| Incorporated by Reference | ||||||||
| Exhibit Number | Exhibit Description | Form | Exhibit | Filing Date/Period End Date | ||||
| 31.1* | Rule 13a-14(a) / 15d-14(a) Certification of Chief Executive Officer. | |||||||
| 31.2* | Rule 13a-14(a) / 15d-14(a) Certification of Chief Financial Officer. | |||||||
| 32.1** | Section 1350 Certification of Chief Executive Officer. | |||||||
| 32.2** | Section 1350 Certification of Chief Financial Officer. | |||||||
| 101.INS* | Inline XBRL Instance Document | |||||||
| 101.SCH* | Inline XBRL Taxonomy Extension Schema Document | |||||||
| 101.CAL* | Inline XBRL Taxonomy Extension Calculation Linkbase Document | |||||||
| 101.DEF* | Inline XBRL Taxonomy Extension Definition Linkbase Document | |||||||
| 101.LAB* | Inline XBRL Taxonomy Extension Label Linkbase Document | |||||||
| 101.PRE* | Inline XBRL Taxonomy Extension Presentation Linkbase Document | |||||||
| 104* | Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101.INS) | |||||||
# Indicates management contract or compensatory plan, contract or arrangement.
* Filed herewith.
**Furnished herewith
42
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
LIFEMD, INC.
| By: | /s/ Justin Schreiber | |
| Justin Schreiber | ||
Chief Executive Officer and Chairman of the Board of Directors (principal executive officer) |
||
| Date: | November 17, 2025 | |
| By: | /s/ Marc Benathen | |
| Marc Benathen | ||
Chief Financial Officer (principal financial officer) |
||
| Date: | November 17, 2025 | |
| By: | /s/ Maria Stan | |
| Maria Stan | ||
Chief Accounting Officer and Controller (principal accounting officer) |
||
| Date: | November 17, 2025 |
43
FAQ
How did LifeMD (LFMD) perform financially in Q3 2025?
LifeMD generated $60.2 million in Q3 2025 revenue, up from $53.3 million in Q3 2024. Gross profit was $52.8 million, and the company reported an operating loss of $2.0 million, improved from a $4.0 million loss a year earlier. Net loss attributable to common stockholders narrowed to $4.6 million, compared with $5.4 million in the prior-year quarter.
What were LifeMD (LFMD)’s results for the first nine months of 2025?
For the nine months ended September 30, 2025, LifeMD reported revenue of $186.98 million, up from $149.34 million in the same 2024 period. Operating loss narrowed to $1.45 million from $14.43 million, while net loss attributable to common stockholders improved to $7.94 million from $18.80 million.
What is LifeMD (LFMD)’s cash and debt position as of September 30, 2025?
As of September 30, 2025, LifeMD held $23.79 million in cash and reported no remaining principal on its convertible long-term debt, after paying the final $14.0 million of Avenue Facility principal on August 5, 2025. Total stockholders’ equity was $3.37 million, a significant improvement from a deficit at December 31, 2024.
How are LifeMD’s telehealth and WorkSimpli segments contributing to revenue?
In Q3 2025, telehealth subscription revenue was $27.30 million (45% of revenue) and telehealth product revenue was $19.98 million (33%). WorkSimpli subscription software revenue contributed $12.89 million (22%). For the nine months, telehealth subscription, telehealth product, and WorkSimpli revenues were $86.45 million, $60.73 million, and $39.79 million, respectively.
Did LifeMD (LFMD) raise equity capital during 2025?
Yes. Under its at-the-market (ATM) Sales Agreement, LifeMD sold 762,990 shares of common stock during Q3 2025, paying about $270 thousand in fees and receiving $8.72 million in net proceeds. As of September 30, 2025, the company reported $44.6 million of remaining capacity under the ATM program.
What does LifeMD say about its liquidity and ability to fund operations?
LifeMD states that its existing cash balance of $23.8 million as of September 30, 2025 is expected to be sufficient to fund planned operating expenses and capital expenditure requirements for at least the next 12 months from the issuance date of the unaudited condensed consolidated financial statements.
Did LifeMD revise any previously issued financial statements?
Yes. LifeMD identified and corrected immaterial errors primarily related to the recording of net revenue as agent in certain third-party pharmacy arrangements and various out-of-period items affecting revenue, deferred revenue, accounts receivable, accrued expenses, and certain tax and non-controlling interest balances. These revisions are reflected in the 2024 and 2025 comparative figures presented.
